Document:

Exhibit 10-18

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately
with the Securities and Exchange Commission.

 

THIS AGREEMENT is made
this          day of                     2007

 

BETWEEN Health Protection Agency,
Centre for Emergency Preparedness and Response, Porton Down, Salisbury, Wilts, SP4 OJG which expression shall include its
successors in title (“HPA”) and

 

Biocontrol Limited, a company
registered in England and Wales (registered number 03452169) whose registered office is at Latimer House, 5 Cumberland Place,
Southampton, SO I5 2BH (“Biocontrol”).

 

WHEREAS

 

		(A)	HPA is in possession of intellectual property in respect
of Bacteriophage for the treatment of bacterial bio films;

 

		(B)	Biocontrol wish to use HPA’s intellectual property referred
to in (A) above to develop therapuetics for the treatment of Pseudomonas infections (Schedule 1).

 

NOW IT IS HEREBY AGREED AS FOLLOWS:

 

		1.	DEFINITIONS AND INTERPRETATION

 

		1.1	In this Agreement and the Schedules hereto the following
expressions shall have the following meanings:

 

		“Affiliate”	means any entity that is controlled
by, controls, or is under common control with HPA or Biocontrol, as the case may be. For such purpose the term “control”
means  (a) direct or indirect ownership of more than fifty percent (50%) of the voting interest in the entity in question,
or more than fifty percent (50%) interest in the income of the entity in question; provided, however, that if local law requires
a minimum percentage of local ownership, control will be established by   direct or indirect beneficial ownership of one hundred
 percent (100%) of the maximum ownership percentage that may, under such local law, be owned by foreign interests; or (b) possession,
directly or indirectly, of the power to direct or cause the direction of management or policies of the entity in question (whether
through ownership of securities or other ownership interests, by contract or otherwise).
	 	 	 
	 	“Combination
Product”	 means any Licensed Product which includes any technology or intellectual property which is or has been
developed by any third party upon which royalties are due from Biocontrol or the sub-licensee.

 

    	Licence:Biocontrol

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately
with the Securities and Exchange Commission.

 

	 	“HPA Patent Application”	means HPA’s applications for patents described in Schedule 1, and any other patents claiming priority from said applications including all continuations, continuations-in-part, divisionals, reissues, re- examinations, extensions, substitutions and/or renewals thereof and any supplementary or additional protection certified as related thereto.
	 	 	 
	 	“HPA Patent”	means any patent granted in respect of the HPA Patent  Application.
	 	 	 
	 	“HPA Phages”	means such bacteriophages of HPA origin as are specified in the Schedule to this agreement, together with all supporting data.
	 	 	 
	 	“HPA Intellectual Property”	means the HPA Patent Application WO2004062677 and  all national filings deriving therefrom
	 	 	 
	 	“Milestone Payments”	means non-recurring payments, excluding royalty payments, made by a third party sub-licensee to Biocontrol in respect of the development of a Licensed Product or a Mixed Product
	 	 	 
	 	“Net Sales”	means the gross invoice price at which a purchaser is invoiced for supply of a Protein Product or Product in a bona fide arms length sale less the costs of packing, transport, insurance, customs duties, allowances for defective products, normal trade discounts and Sales, Value Added or other similar taxes separately charged on the invoice or income paid to Biocontrol as royalties on sales of Licensed Product or Mixed Product or Combination Product as the case may be.
	 	 	 
	 	“Licensed Product”	means any therapeutic product for the treatment or prevention of Pseudomonas infection in cystic fibrosis patients produced by Biocontrol or its Affiliates or sublicensees using the HPA Patent or the HPA Patent Application
	 	 	 
	 	“Mixed Product”	means any product developed by Biocontrol or its licensee for any application which is a mixture or combination containing more than one active biological agent where at least one of those agents is one of the HPA Phages
	 	 	 
	 	“Territory”	means all the countries of the world

 

		1.2	References to Clauses and Schedules are to clauses and
schedules in this Agreement. Headings are for convenience only and have no legal effect.

 

 

    	Licence:Biocontrol

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately
with the Securities and Exchange Commission.

 

		1.	3 References to the singular shall include the plural
and references to the plural shall include the singular.

 

		2.	GRANT
                                         OF LICENCE

 

		2.1	HPA grants to Biocontrol and Biocontrol accepts an
exclusive, worldwide royalty bearing licence of the HPA Intellectual Property and the HPA Phages and to use the HPA Intellectual
Property to research, develop, make and
have made Licensed Products and /or Mixed Products and to use, sell, exploit and commercialise
Licensed Products and/or Mixed Products in the Territory.

 

		2.2	Biocontrol may, upon giving HPA notice in writing, grant
sublicences within the scope of its own rights granted under this Licence Agreement. Such notice shall contain details of the
intended sublicensee and the terms of the sublicence. Biocontrol guarantees due performance of its obligations arising from any
sublicences that it grants under this Licence Agreement.

 

		2.3	Biocontrol shall (subject to Clause 5 below) ensure that
in consideration of all sublicences granted by Biocontrol in accordance with Sub-clause 2.2 the sublicensee shall pay to the HPA
(or to Biocontrol for onward transmission to HPA under this agreement) royalties as calculated in Clause 5.

 

		2.4	Biocontrol shall procure that all sublicences granted
by Biocontrol in accordance with Sub-clause 2.2 include obligations of secrecy no less onerous than those set out in Clause 9
of this Licence Agreement, except in that the term of such confidentiality may be reduced at the specific request of a sublicensee,
such request to be notified to HPA.

 

		2.5	Biocontrol shall ensure that all sublicences granted
by Biocontrol in accordance with Sub-clause 2.2 shall transfer to HPA as licensor upon the event of termination of this Agreement
under Clause 7 of this Agreement.

 

		3.	PATENT
                                         MAINTENANCE

 

		3.1	HPA and Biocontrol shall jointly maintain the HPA
Patent and the HPA Patent Application as detailed in this Clause and at Biocontrol’s expense until such time as any assignment
is completed under Clause 11.6, at which time maintenance shall become the responsibility of Biocontrol, at Biocontrol’s expense.
Prior to any such assignment, HPA shall provide copies of all relevant documentation to Biocontrol, and HPA confirms that all
renewals and other documentation required for maintenance of the HPA patent shall be completed in a timely fashion by HPA or HPA’s
agents. Any changes in claims or in the scope of the HPA patent (whether resulting from patent office examination or from any
other cause) prior to any assignment under Clause 11.6 shall be agreed in advance between HPA and Biocontrol. Following any assignment
under Clause 11.6, Biocontrol shall arrange for documentation relating to the HPA patent to be sent to Biocontrol and shall then
provide full copies to HPA and shall consult in advance with HPA on any changes to the claims or in the scope of
the HPA patent..

 

		3.2	Either party which becomes aware

 

    	Licence:Biocontrol

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately
with the Securities and Exchange Commission.

 

	 	(a)	of any claim that use of the HPA Patent of the HPA Patent Application infringes the rights of any third party, or

 

		(b)	of any infringement by a third party of the HPA Patent
of the HPA Patent Application

 

shall within ten (10) working
days inform the other and the parties shall promptly consult. Biocontrol having consulted with HPA shall at its sole discretion
decide what action if any it will take in respect of the claimed or actual infringement. Biocontrol shall bear the cost of such
action provided that Biocontrol shall be entitled to deduct any of its ensuing direct expenses from future royalty and milestone
sums payable to HPA. Any damages awarded or settlements paid to Biocontrol arising from Biocontrol’s action shall be applied
firstly to reimburse Biocontrol for any of its direct costs not recovered from HPA and secondly to reimburse HPA for any royalties
or milestone sums withheld by Biocontrol, any excess being the property of Biocontrol. If Biocontrol decides to take no action
in respect of the claimed or actual infringement HPA shall be entitled at its own expense to take such action as it chooses in
respect of the Intellectual Property provided that any resulting damages awarded or settlements paid to HPA shall be the property
of HPA.

 

		3.3	Biocontrol shall notify and keep HPA fully informed of
any decision and action taken by Biocontrol pursuant to its rights under Clause 3.3.

 

		4.	UNDERTAKINGS

 

		4.1	Biocontrol hereby agrees at its own expense to conduct
development activity and to commence clinical trials to support the development of a Licensed Product, and to use all reasonable
commercial endeavours to develop or to facilitate the development of a Licensed Product. It is understood that this may involve
consideration of a Mixed Product or a Combination Product.

 

		4.2	Biocontrol shall keep HPA informed

 

		(a)	of its actions and progress in meeting its obligations
under Clause 4.1 at annual meetings between appropriate representatives of both parties for which it will provide
such written reports as HPA shall reasonably request, and

 

		(b)	of the dates on which any of the events occuras specifiedin
Clause 5.1 (a) other than the signing of this Agreement.

 

		4.3	HPA shall make available to Biocontrol such facilities,
resources and staff as may be required to host visits by members of Biocontrol staff for the purposes of furthering the work of
the project, the timing and duration of such visits to be agreed in advance between HPA and Biocontrol. Such visits may be for
up to a maximum of 80 hours per year for each member of the Biocontrol research staff. Where direct supervision or technical support
is required for a substantive element of the work to be undertaken during such visits then Biocontrol shall pay for such time
at the rate of £304 per day, (and pro rata for smaller or larger amounts of time where required) such amounts to be agreed
in advance and varied annually according to HPA financial policy. Such payments shall be made on provision by HPA of an invoice
specifying the hours worked during the visit in question.

 

    	Licence:Biocontrol

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately
with the Securities and Exchange Commission.

 

		5.	ROYALTIES
                                         AND MILESTONE PAYMENTS

 

		5.1	In consideration for the licence hereby granted, Biocontrol
shall pay to HPA

 

		(a)	the following milestone sums when the events specified
first occur in respect of any Protein Product or Product

 

		(i)	[*****]

		(ii)	[*****]

 

		(b)	royalties of [*****]

		(c)	a further royalty of [*****]

		(d)	In respect of Mixed Product, payment of [*****]

		(e)	and for Combination Product of a royalty equivalent to
[*****]

 

		5.2	Biocontrol shall provide to HPA within forty (40) days
following the end of each December and June or the date of expiry or termination of this Agreement statements of Net Sales of
Products including a list of Net Sales by country and of the royalties due as set out in Clause 5.1 in respect of the preceding
half year period.

 

		5.3	Biocontrol shall make all payments in respect of royalties
specified in Clause 5.1 at the same date as the statements required under Clause 5.2.

 

		5.4	All payments due under this Agreement shall be made by
Biocontrol to HPA in full, provided however to the extent that any payment hereunder is subject to deduction of tax according
to law or regulation in the country from which the remittance is made, and a treaty or other provision exists between that country
and the country where the remittance is received, for the avoidance of double taxation Biocontrol shall have the right to make
such deduction of tax from such payment and shall for each such deduction supply to HPA a certificate or other documentary evidence
to enable HPA to recover the tax or otherwise avoid double taxation on the payment concerned.

 

    	Licence:Biocontrol

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately
with the Securities and Exchange Commission.

 

		6.	RECORDS

 

Biocontrol agrees to
keep true and accurate records and books of account containing all data necessary for the determination of royalties payable
hereunder which records and Licence: Biocontrol books of account shall upon reasonable notice
of HPA be open during business hours for inspection by a duly authorised independent agent for the purpose of verifying the
accuracy of Biocontrol’s reports hereunder. HPA’s duly authorised independent agent may take information as should properly
have been contained in any statement required to be furnished by Biocontrol to HPA. HPA shall be solely responsible for the
costs of employing a duly authorised agent unless appreciable errors are detected (appreciable is assumed to be a variation
of 10% or more to the detriment of HPA) in which event Biocontrol shall reimburse HPA for all its reasonable costs in
employing such an agent.

 

		7.	DURATION,
                                         DEFAULT, TERMINATION AND LOSS OF EXCLUSIVITY

 

		7.1	This Agreement shall continue in full force and effect
from the date hereof until the last to expire of any Intellectual Property owned and registered by HPA as provided under Sub-clause
3.1 from the date hereof, subject to the provisions for termination in this Clause 7.

 

		7.2	In the event that Biocontrol fails to make any royalty
or milestone sum payments as provided in Clause 5, then it shall pay interest to HPA on any sums outstanding at four per centum
per annum above HSBC base rate for the time being until payment is made in full.

 

		7.3	In the event that:

 

		(a)	before the development of any Licensed Product or Mixed
Product or Combination Product Biocontrol enters into liquidation whether compulsory or voluntary (save for the purpose of reconstruction
or amalgamation) or has a receiver appointed over all or part of its assets or ceases for any reason to carry on the whole or
a significant part of its business then all rights given to Biocontrol under this Agreement shall cease and the said license granted
to Biocontrol by the HPA shall be deemed null and void without prejudice to any pre-existing sub-licences the benefit of which
shall then be transferred to HPA .

 

		(b)	Biocontrol fails to comply with its obligations in Clauses 4, 5 and 9 of this Agreement 

 

then HPA may acting reasonably at its option on written notice to Biocontrol

 

		(i)	terminate this Agreement with immediate effect, or

 

(ii)
render the licence granted under Clause 2 non-exclusive with immediate effect provided that HPA shall give Biocontrol thirty
(30) days notice of its intention to give such a notice so that Biocontrol may make representations in respect of such notice
and HPA shall consider those representations before determining its decision..

 

		8.	PROVISIONS
                                         AFTER TERMINATION

 

		8.1	The expiry or termination of this Licence Agreement shall
not terminate any obligation which, expressly or by nature, arises on or continues after expiry or termination and failure
by either party to terminate this Licence Agreement for any default or breach by the other shall not condone that (or any other)
default or breach.

 

    	Licence:Biocontrol

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately
with the Securities and Exchange Commission.

 

		8.2	Biocontrol’s obligations to keep records, supply auditors’
certificates, and to permit inspection of records, shall remain in force for six (6) years after expiry or termination.

 

		9.	CONFIDENTIALITY

 

		9.1	For the purposes of this Clause 9 “Confidential
Information” means any information of a confidential nature disclosed in writing or orally by either party to the other party
whether before or after the date of this Agreement including without limitation any information relating to the business affairs
of either party.

 

		9.2	During the term of this Agreement and for a period of
seven (7) years from the date of signature of this Agreement, whichever is the longer for any reason whatsoever each party shall:

 

		(a)	keep the Confidential Information confidential

 

		(b)	not disclose the Confidential Information to any third
party other than with the prior written consent of the providing party or as otherwise provided by this Agreement.

 

		(c)	not use the Confidential Information for any purpose
other than the performance of its obligations or as otherwise provided under this Agreement.

 

		9.3	The obligations contained in sub-clause 9.2 shall not
apply to any Confidential Information which

 

		(a)	at the date of this Agreement or at any time after the
date of this Agreement comes into the public domain other than through breach of this Agreement by HPA or Biocontrol or any other
recipient

 

		(b)	can be shown by either party (the first party) to the
reasonable satisfaction of the other to have been known by the first party before disclosure, or

 

		(c)	subsequently comes lawfully into the possession of either
party from a third party.

 

		10.	NO LIABILITY

 

		10.1	From the date hereof, Biocontrol takes full responsibility
for ensuring that all Licensed Products shall be free of any defect, of satisfactory quality and fit for the purpose for which
they may be bought or used (within any national legal or regulatory requirements) and shall indemnify and keep indemnified HPA
and its officers or employees against all costs, claims, damages or expenses incurred by HPA or for which HPA may become liable
after the date of this Licence Agreement relating to the use of the HPA Patent or to the manufacture, marketing, selling and disposal
of Licensed Product by the Licensee and its Affiliates and sublicensees (except to the extent that such claims relate to death
and personal injury caused by the negligence of HPA).

 

    	Licence:Biocontrol

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately
with the Securities and Exchange Commission.

 

		8.2	Biocontrol shall, from the date of the first sale of
Licensed Products and/or Mixed Products as the case
may be and while this Licence Agreement is in force and for 6 months after its expiry
or termination, in order to alleviate the possibility of a claim against HPA (or its officers or employees), keep in force adequate
insurance with a reputable insurance company against all risks referred to in Sub-clause 10.1.

 

		8.3	Biocontrol shall on
request provide HPA evidence of payment of the last premium and of the extent of insurance
cover in respect of such policy, and in the event of any non- payment or non-production by Biocontrol, HPA may pay the renewal
premium, or arrange alternative insurance, and Biocontrol shall repay the premium to HPA on demand including any reasonable expenses
incurred by HPA.

 

		9.	GENERAL
                                         PROVISIONS

 

		9.1	Conversion into Sterling

 

All sums payable hereunder
shall be paid in pounds sterling and any Net Sales not expressed in sterling shall be converted into sterling at the official rate
of exchange of the Royal Bank of Scotland at the close of business on the last day of the calendar quarter during which Protein
Products or Products were sold.

 

		9.2	Force Majeure

 

		(a)	If either party is prevented from fulfilling its obligations
under this Agreement by reason of any supervening event beyond its control including but not limited to war national emergency
flood earthquake strike or lockout the party unable to fulfil its obligations shall immediately give notice of this to the other
party and shall do everything in its power to resume full performance.

 

		(b)	On such notice being given neither party shall be deemed
to be in breach of its obligations under this Agreement.

 

		9.3	Whole Agreement

 

This Agreement contains the
whole agreement between the parties and supersedes any prior written or oral agreement between them in relation to its subject
matter and the parties confirm that they have not entered into this Agreement on the basis of any representations that are not
expressly incorporated into this Agreement.

 

		9.4	No modification

 

This Agreement may not be modified
except by an instrument in writing signed by both of the parties.

 

		9.5	Assignment

 

		(a)	This Agreement may not be assigned by Biocontrol without
the agreement of HPA which shall not be unreasonably withheld.

 

    	Licence:Biocontrol

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately
with the Securities and Exchange Commission.

 

		(b)	This Agreement may be assigned by HPA provided that the
Assignee shall, prior to such assignment, accept in writing to Biocontrol all relevant rights and obligations of Biocontrol under
this Agreement.

 

		9.6	Possible assignment of the HPA Patent

 

HPA agrees to review potential
assignment of the HPA Patent twelve (12) months after the date hereof.

 

		9.7	Invalidity and severability

 

If a provision, clause or application
of this agreement shall be held unlawful, invalid or unenforceable in whole or in part by any court or other competent authority
such provision, clause or application shall be deemed severable and this Agreement shall continue to be valid as to all other provisions,
clauses or applications and the Parties shall in good faith negotiate a valid and enforceable replacement for the severed provision,
clause or application which replacement shall be designed to achieve as nearly as possible the same commercial objective as the
original.

 

		9.8	Arbitration

 

Any dispute arising our of or
in connection with this contract, including any question regarding its existence, validity or termination, shall be referred to
and finally resolved by arbitration under the Rules of the LCIA, which Rules are deemed to be incorporated by reference into this
clause. The number of arbitrators shall be one. The seat, or legal place, of arbitration shall be London. The governing law of
the contract shall be the substantive law of England. The award shall be final and binding upon the parties and without appeal
to the ordinary courts. The award shall be enforceable by any court having jurisdiction.

 

		9.9	Notices

 

		(a)	Any notice consent or the like required or permitted to be given under this Agreement shall
                                                                                   not be binding unless in writing and may be given personally or sent to the party to be notified by pre-paid first class post
                                                                                   or by facsimile transmission at its address as set out above or as otherwise notified in accordance with this clause

 

		(b)	Notice sent by post in accordance with this clause shall
be deemed given at the commencement of business on the fifth (5th) business day next following its posting

 

		(c)	Notice sent by
facsimile transmission in accordance with this clause shall be deemed given at the time of actual transmission

 

		(d)	Notice sent to
HPA shall be addressed to the Head of Business Development, HPA, Centre for Emergency Preparedness and Response, Porton Down,
Salisbury, Wiltshire, SP4 OJG.

 

		(e)	Notice sent to
Biocontrol shall be addressed to Biocontrol Limited. At its registered office for the attention of the Chief Scientific Officer

 

    	Licence:Biocontrol

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately
with the Securities and Exchange Commission.

 

		9.10	VAT

 

All sums payable to HPA under
this Agreement are exclusive of VAT which shall where applicable be paid in addition at the rate in force at the due time for payment
subject to HPA supplying a VAT invoice.

 

		9.11	No Agency or Partnership

 

The parties are not joint venturers
and neither Biocontrol nor HPA is entitled to act as the others agent nor shall either be liable in respect of any representation
act or omission of the other of whatever nature.

 

		9.12	Contracts (Rights of Third Parties) Act 1999

 

This Agreement does not create
any rights under the Contracts (Rights of Third Parties) Act 1999, which are enforceable by any person who is not a party to it.

 

		9.13	Warranties

 

Nothing in this Agreement constitutes
a guarantee or warranty by HPA that:

 

		(a)	any patent or claim will be granted on the basis of the
HPA Patent Application, that any such patent or claim subsequently granted will be valid, or if granted will be kept in force;
or

 

		(b)	research, development, manufacture, sale, possession
or use of Licensed Products does not infringe any patents or other rights not owned by HPA (but HPA does not know of any such
rights).

 

		9.14	Failure to Exercise Rights

 

The failure to exercise or delay in exercising a right
or remedy under this Agreement shall not constitute a waiver of the right or remedy or a waiver of any other rights or remedies
and no single or partial exercise of any right or remedy under this Agreement shall prevent any further exercise of the right or
remedy or the exercise of any other right or remedy.

 

	Signed for and on behalf of Health Protection Agency:
	Signature: 
	Name (capitals): Position:	T R HARRY
	 
	Date:	3/7/07
	Signed for and on behalf of Biocontrol Limited:

 

    	Licence:Biocontrol

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately
with the Securities and Exchange Commission.

 

	Signature:	 
	 	 
	Name (capitals):	CAROLINE ANN WILLIAMS
	 	 
	Position:	DIRECTOR
	 	 
	Date:	3/7/07

 

    	 

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately
with the Securities and Exchange Commission.

 

Schedule 1 Relevant Patent
Applications

 

International publication number
WO2004/062677 A1

 

European publication number EP1587520,
application number EP 04701383.4

 

US publication number 2006/0140911,
application number US10/541716

 

Relevant bacteriophage

 

The following bacteriophage have been deposited with
the European Collection of Animal Cell Cultures (ECACC)

 

	O GH4	ECACC accession number 02121203
	 	 
	<t> GH6	 ECACC accession number 02121202
	 	 
	GH13	ECACC accession number 02121201
	 	 
	GH14	ECACC accession number 02121204Exhibit 10.19

 

 

	 	Shareholder Sale Agreement
	 	 
	 	BETWEEN
	 	 
	 	The parties listed in Schedule 1 (Vendors)
	 	 
	 	AND
	 	 
	 	Anthony Smithyman and Margaret Smithyman (Managers)
	 	 
	 	AND
	 	 
	 	Ampliphi Australia Pty Ltd (Purchaser)
	 	 
	 	AND
	 	 
	 	Ampliphi Biosciences Corporation (Ampliphi)
	 	 
	 	AND
	 	 
	 	Special Phage Holdings Pty Ltd (Company)
	 	 
	 	MILLS OAKLEY LAWYERS
	 	Level 6, 530 Collins
    Street
	 	MELBOURNE VIC 3000
	 	Telephone: 03 9670
    9111
	 	Facsimile:  03
    9605 0933
	 	DX 558 MELBOURNE
	 	www.millsoakley.com.au

 

    	 	 

    	 	Shareholder Sale Agreement

    

 

TABLE OF CONTENTS

 

	1	Definitions and Interpretation	1
	 	1.1	Definitions	1
	 	1.2	Interpretation	4
	 	1.3	Inclusive
    expressions	5
	 	 	 
	2	Conditions Precedent	5
	 	2.1	Conditions	5
	 	2.2	Notice	6
	 	2.3	Reasonable
    endeavours	6
	 	2.4	Waiver	6
	 	2.5	Termination	7
	 	2.6	No binding
    agreement for transfer	7
	 	 	 
	3	Sale and  Purchase	7
	 	3.1	Sale of
    Safe Shares	7
	 	3.2	Associated
    rights	7
	 	3.3	Purchase
    Price	7
	 	3.4	Consideration	8
	 	3.5	Purchaser
    and Ampliphi	8
	 	 	 
	4	Completion	8
	 	4.1	Time and
    Date	8
	 	4.2	Vendors’
    obligations at Completion	8
	 	4.3	Company
    board meeting	9
	 	4.4	Purchaser’s
    obligations at Completion	9
	 	4.5	Purchaser
    board meeting	9
	 	4.6	Completion
    simultaneous	9
	 	 	 
	5	Period after Completion	10
	 	5.1	Exercise of rights of registered shareholder	10
	 	 	 
	6	Vendor Warranties	10
	 	6.1	Giving of Vendor Warranties	10
	 	6.2	Independent warranties	10
	 	6.3	Reliance	10
	 	 	 
	7	Manager’s Contingent Shares	10
	 	 	 
	8	Escrow Shares	11
	 	8.1	Escrow Shares	11
	 	8.2	Escrow restrictions	11
	 	 	 
	9	Limitations of Liability	11
	 	 	 
	10	Satisfaction of Claims	12
	 	 	 
	11	Dispute Resolution	12
	 	 	 
	12	Purchaser Warranties	14
	 	12.1	Giving of Purchaser Warranties	14
	 	12.2	Independent warranties	14
	 	12.3	Reliance	15
	 	 	
	13	Termination	15
	 	13.1	Termination by the Purchaser	15
	 	13.2	Termination by the Vendors	15

 

    	Mills Oakley Lawyers Pty Ltd ©	Page i

    	 	Shareholder Sale Agreement

    

 

	14	Confidentiality and Announcements	16
	 	14.1	Dictionary	16
	 	14.2	Confidentiality obligations	16
	 	14.3	Announcements	16
	 	14.4	Exceptions	16
	 	14.5	Survival	17
	 	 	 
	15	GST	17
	 	15.1	Definitions	17
	 	15.2	Consideration is GST Exclusive	17
	 	15.3	Taxable Supply	17
	 	15.4	Tax Invoice	17
	 	15.5	Penalties and Interest	17
	 	15.6	Reimbursement and Indemnity Payments	17
	 	 	 
	16	Notices	17
	 	16.1	Form of Notice	17
	 	16.2	Vendor Representative	18
	 	16.3	Appointment of Escrow Agent	19
	 	16.4	Address for service	19
	 	 	 	 
	17	General	 	19
	 	17.1	Further assurances	19
	 	17.2	Severability	19
	 	17.3	Non-merger of provisions	19
	 	17.4	Waiver	19
	 	17.5	Entire agreement	20
	 	17.6	No amendments without agreement	20
	 	17.7	Assignment	20
	 	17.8	Costs, expenses and stamp duty	20
	 	17.9	Counterparts	20
	 	17.10	Jurisdiction	20
	 	17.11	Attorneys	20

 

	Schedule 1	Vendors, Sale Shares and Consideration	21
	 	 	 
	Schedule 2	Vendor Warranties	31
	 	 	 
	Schedule 3	Purchaser Warranties	37
	 	 	 
	Schedule 4	Contingent Shares	45
	 	 	 
	Execution Page	 	48
	 	 	 
	Annexure A	Application to Subscribe	 
	 	 	 
	Annexure B	Sophisticated Investor Certificate	 
	 	 	 
	Annexure C	Consultancy Agreement	 
	 	 	 
	Annexure D	Escrow Agreement	 

 

    	Mills Oakley Lawyers Pty Ltd ©	Page ii

    	 	Shareholder Sale Agreement

    

  

Parties

 

THE PARTIES LISTED IN SCHEDULE 1

(Vendors)

 

ANTHONY SMITHYMAN AND MARGARET SMITHYMAN

	of 14 Norfolk Avenue, Collaroy New South Wales
    2097	(Managers)

 

AMPLIPHI AUSTRALIA PTY LTD (ACN 159
983 356)

of C/O Mills Oakley Lawyers, Level 6,
530 Collins Street, Melbourne, VIC 3000

(Purchaser)

 

AMPLIPHI BIOSCIENCES CORPORATION

of 800 E. Leigh St 54 Richmond, VA 23219,
United States of America

(Ampliphi)

 

SPECIAL PHAGE HOLDINGS PTY LTD (ACN
102 575 511)

of Unit 5, 14 Kurraba Road, Neutral Bay,
NSW 2089

(Company)

 

Background

 

		A.	The Vendors own
                                         the Sale Shares as set out in Schedule 1.

 

		B.	The Purchaser has
                                         offered to buy the Sale Shares on the terms and conditions of this agreement.

 

		C.	All the issued Shares
                                         in the Purchaser are legally and beneficially owned by Ampliphi.

 

Terms and conditions

 

	1	Definitions
    and Interpretation

 

		1.1	Definitions

 

In this agreement, unless the
context otherwise requires:

 

Acceptance Forms means the forms to
be completed by a Vendor to constitute the Vendor’s acceptance of the Offer, which will include a Share Transfer and an
Application to Subscribe for the Consideration Shares (in the form attached as Annexure A).

 

Business Day means
a day (other than a Saturday, Sunday or public holiday) on which banks are open for general banking business in Melbourne, Victoria,
Sydney, New South Wales and the state of Virginia in the United State of America.

 

Claim includes a claim, notice, demand,
action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award, damage, loss, cost, expense or liability
however arising, whether present, unascertained, immediate, future or contingent and whether based in contract, tort or statute.

 

Cleared Funds means a balance in an
account that is able to be withdrawn or used in financial transactions.

 

Company Material Adverse Change means
an event or series of events between the date of this agreement and the Completion Date which has had a material adverse effect
on the business of the Company or the financial condition and results of operation of the Company.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 1

    	 	Shareholder Sale Agreement

    

 

Completion means completion of the
sale and purchase of the Sale Shares on the Completion Date in accordance with clause 4.

 

Completion Date means the day that
is the next Business Day following the day on which each of the Conditions Precedent have been satisfied or waived or such other
date as the Vendor Representative and the Purchaser agree in writing.

 

Completion Shares
mean the shares of common stock in the issued share capital of Ampliphi due from the Purchaser to the Vendors as consideration
at Completion and which will be issued directly to the Vendors on Completion, as set out in Schedule 1

 

Conditions Precedent has the meaning
given in clause 2.1.

 

Consideration Shares means the total
shares of common stock in the issued share capital of Ampliphi which are due from the Purchaser to the Vendors as consideration,
as set out in Schedule 1, including the Completion Shares, the Contingent Shares and the Escrow Shares.

 

Contingent Shares
means the shares of common stock in the issued share capital of Ampliphi that are due from the Purchaser to the Managers as consideration
in the circumstances described in clause 7 and as set out in Schedule 4.

 

Controller means, in relation to an
entity, a person or a party:

 

		(a)	a receiver, receiver and manager, administrator or liquidator
                                         (whether provisional or otherwise) of that person or that person's property; or

 

		(b)	anyone else who (whether or not as agent for the person) is
                                         in possession, or has control, of that person's property to enforce an Encumbrance.

 

Corporations Act means the Corporations
Act 2001 (Cth).

 

Duty means any
stamp, transaction or registration duty or similar charge imposed by any Government Agency and includes, but is not limited to,
any interest, fine, penalty, charge or other amount imposed in respect of the above but excludes any Tax.

 

Encumbrance means an interest or power:

 

		(a)	reserved in or over an interest
                                         in any asset including any retention of title; or

 

		(b)	created or otherwise arising in or over any interest in any
                                         asset under a bill of sale, mortgage, charge, lien, pledge, trust arrangement, power,
                                         assignment, hypothecation, security interest or preferential right,

 

by way of security for the payment of a debt, any
other monetary obligation or the performance of any other obligation, and includes, but is not limited to, any agreement to grant
or create any of the above.

 

End Date means 31 October 2012, or
such later date as agreed in writing by the Purchaser, Ampliphi and the Vendor Representative.

 

Escrow Agent means Computershare Trust
Company N.A. or such other agent as agreed by the Purchaser, Ampliphi and the Vendor Representative prior to the Completion Date.

 

Escrow Agreement
means the agreement between the Purchaser, Ampliphi, the Vendor Representative and the Escrow Agent setting out the terms on which
the Escrow Agent will hold and release the Escrow Shares and the Contingent Shares to the Vendors and Managers in the form as
set out in Annexure D. All costs of the Escrow Agent under the Escrow Agreement will be borne by the Purchaser.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 2

    	 	Shareholder Sale Agreement

    

 

Escrow Shares
means 8 million shares of common stock in Ampliphi that are due from the Purchaser to the Vendors as consideration (subject to
this agreement), as set out in Schedule 1 and dealt with under clause 8.

 

Execution Date
means the date of this agreement.

 

Government Agency means any government
or governmental, semi governmental, administrative, fiscal, or judicial body, department, commission, authority, tribunal, agency
or entity.

 

GST has the meaning
it has in the GST Act.

 

GST Act means
the A New Tax System (Goods and Services Tax) Act 1999 (Cth).

 

GST Law has the
meaning it has in the GST Act.

 

Insolvency Event
means, in relation to an entity, a person or a party, any one or more of the following events or circumstances:

 

		(a)	being in liquidation or provisional
                                         liquidation or under administration;

 

		(b)	having a Controller or analogous
                                         person appointed to it or any of its property;

 

		(c)	being taken under section 459F(1) of the Corporations Act to
                                         have failed to comply with a statutory demand;

 

		(d)	being unable to pay its debts or
                                         being otherwise insolvent;

 

		(e)	becoming an insolvent under administration, as defined in section
                                         9 of the Corporations Act;

 

		(f)	entering into a compromise or arrangement with, or assignment
                                         for the benefit of, any of its members or creditors;

 

		(g)	any analogous event or circumstance
                                         under the laws of any jurisdiction; or

 

		(h)	taking any step or being the subject of any action that is
                                         reasonably likely to result in any of the above occurring (including the convening of
                                         a meeting or presenting a petition or order for winding up),

 

unless such event or circumstance occurs as part
of a solvent reconstruction, amalgamation, compromise, arrangement, merger or consolidation approved by the other party (which
approval is not to be unreasonably withheld or delayed).

 

Liability includes all liabilities,
losses, damages, costs, interest, fees, penalties, fines, assessments, forfeiture and expenses of whatever description (whether
actual, contingent or prospective).

 

Loan Repayment Deed
means the agreement between Cellabs Pty Ltd, the Company and Ampliphi dated on or about the date of this agreement. The Loan Repayment
Deed sets out the terms for repayment by Ampliphi of the debt due by the Company to Cellabs Pty Ltd.

 

Loss means any loss, including any
damage, claim, action, liability, cost, expense, charge, penalty, outgoing or payment (including in relation to Duty or Tax) and
legal costs and expenses.

 

Managers means Anthony Smithyman and
Margaret Smithyman, both of whom are also Vendors.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 3

    	 	Shareholder Sale Agreement

    

 

Management Vendors’ Warranty Deed
means the deed between the Managers, the Purchaser and Ampliphi dated on or about the date of this agreement.

 

Market Value means the fair market
value of one Consideration Share as determined by the Board of Directors of Ampliphi, acting in good faith; provided, however,
that where a public market exists for equivalent shares of Ampliphi at the date of determination, the fair market value per
Consideration Share shall be the average of the closing bid and asking prices of the common stock or the closing price quoted
on the national securities exchange or quotation service on which the common stock is listed or quoted as published in the Wall
Street Journal, as applicable, for the relevant following period:

 

		(a)	in respect of a Claim that is notified within 6 months from
                                         Completion Date, the period from Completion Date to the date that notice is given of
                                         the Claim; and

 

		(b)	in respect of a Claim that is notified more than 6 months from
                                         Completion Date, the period from Completion Date to the date that is six months after
                                         Completion Date..

 

Offer means the offer by the Purchaser
to the Vendors to buy the Sale Shares on the terms and subject to the conditions set out in this agreement.

 

Purchase Price is described in clause
3.3.

 

Purchaser Material Adverse Change means
an event or series of events between the date of this agreement and the Completion Date which has had a material adverse effect
on the business of Ampliphi or the Purchaser or the financial condition and results of operation of Ampliphi or the Purchaser.

 

Purchaser Warranties means the warranties
and representations set out in Schedule 3.

 

Sale Shares means the shares held by
the Vendors in the Company as set out in Schedule 1.

 

Share Transfer means a written transfer
form for the transfer of a Vendor’s Sale Shares to the Purchaser. The Share Transfer will be in the form which has been
negotiated and agreed between the Vendor Representative and the Purchaser.

 

State means the state of New South
Wales in the Commonwealth of Australia.

 

Tax means any tax, levy, charge,
impost, fee, deduction, compulsory loan or withholding, which is assessed, levied, imposed or collected by any Government Agency
and includes, GST, any interest, fine, penalty, charge, fee or any other amount imposed on, or in respect of, any of the above,
but excludes Duty and any income tax of a party.

 

Tax Law means any Law relating to Tax.

 

US Securities Act means the U.S. Securities
Act of 1933, as amended.

 

Vendor Representative means Anthony
Smithyman.

 

Vendor Warranties means the warranties
and representations set out in Schedule 2.

 

		1.2	Interpretation

 

In this agreement headings and words in bold are
inserted for convenience and do not affect the interpretation of this agreement and unless the contrary intention appears:

 

		(a)	a reference to this agreement or
                                         another instrument includes any variation or replacement of any of them;

 

		(b)	a reference to a statute, ordinance,
                                         code or other law includes regulations and other instruments under it and consolidations,
                                         amendments, re enactments or replacements of any of them;

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 4

    	 	Shareholder Sale Agreement

    

 

		(c)	the singular includes the plural
                                         and vice versa;

 

		(d)	the word 'person' includes a firm, a body corporate, an unincorporated
                                         association or an authority;

 

		(e)	a reference to a person includes a reference to the person’s
                                         executors, administrators, successors, substitutes (including persons taking by novation)
                                         and assigns;

 

		(f)	if a period of time is specified and dates from a given day
                                         or the day of an act or event, it is to be calculated exclusive of that day;

 

		(g)	a reference to a day is to be interpreted as the period of
                                         time commencing at midnight and ending 24 hours later;

 

		(h)	if an act prescribed under this agreement to be done by a party
                                         on or by a given day is done after 5.00pm on that day, it is taken to be done on the
                                         next day;

 

		(i)	if an event must occur on a stipulated day that is not a Business
                                         Day then the stipulated day will be taken to be the next Business Day;

 

		(j)	a reference to time is a reference
                                         to Sydney time;

 

		(k)	a reference to any thing (including
                                         any amount) is a reference to the whole and each part of it and a reference to a group
                                         of persons is a reference to any one or more of them;

 

		(l)	a reference to a part, clause,
                                         party, attachment, exhibit or schedule is a reference to a part and clause of, and a
                                         party, attachment, exhibit and schedule to, this agreement and a reference to this agreement
                                         includes any attachment, exhibit and schedule;

 

		(m)	a reference to $ is to Australian
                                         currency and any amount payable under this agreement is payable in Australian currency,
                                         unless denominated or specified otherwise; and

 

		(n)	terms defined in the Corporations
                                         Act are used in this agreement with the same defined meaning.

 

		1.3	Inclusive
                                         expressions

 

Specifying anything in this agreement
after the words ‘including’, ‘includes’ or ‘for example’ or similar expressions does not limit
what else is included unless there is express wording to the contrary.

 

	2	Conditions
    Precedent

 

		2.1	Conditions

 

Completion is conditional upon
the satisfaction of the following:

 

		(a)	Acceptance of Offer: Vendors
                                         holding at least 90% of the Sale Shares accept the Offer by signing and returning to
                                         the Company the Acceptance Forms and this agreement;

 

		(b)	due diligence: the Purchaser notifies the Vendor Representative
                                         that it has completed its due diligence investigations to its satisfaction;

 

		(c)	options: all options that have been issued in respect
                                         of the capital of the Company have been exercised to the satisfaction of the Purchaser
                                         or the period during which those options can be exercised has expired;

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 5

    	 	Shareholder Sale Agreement

    

 

		(d)	Management
                                         Vendors’ Warranty Deed: the Management Vendors’ Warranty Deed has been
                                         properly executed by each of the Managers;

 

		(e)	Loan Repayment
                                         Deed: the Loan Repayment Deed has been executed by each of the parties named in that
                                         agreement;

 

		(f)	No disclosure
                                         required: certificates in the form set out at Annexure B have been duly completed
                                         and executed by Vendors (where applicable) and Ampliphi notifies the Vendor Representative
                                         that Ampliphi is satisfied that the Consideration Shares can be issued without
                                         disclosure under the Corporations Act ;

 

		(g)	Ampliphi meeting:
                                         a meeting of the board of directors of Ampliphi has been convened and has approved
                                         the issue of the Consideration Shares to the Vendors and a true copy of the minutes of
                                         the Board evidencing approval of the issue of the Consideration Shares has been provided
                                         by the Purchaser to the Vendor Representative;

 

		(h)	Escrow Agent:
                                         the Escrow Agent is appointed and the Escrow Deed has been signed by all parties;

 

		(i)	Consultancy
                                         Agreement – Tony Smithyman: Ampliphi has appointed Tony Smithyman as a consultant,
                                         effective from the Completion Date, on the terms contained in the agreement attached
                                         as Annexure C; and

 

		(j)	other approvals:
                                         all other regulatory or other approvals that the parties mutually agree are necessary
                                         in connection with the transactions contemplated by this agreement are obtained,

 

(collectively, Conditions
Precedent).

 

		2.2	Notice

 

The Purchaser and the Vendor
Representative must promptly notify each other in writing if either one of them or they become aware that any Condition Precedent
has been satisfied or has become incapable of being satisfied.

 

		2.3	Reasonable endeavours

 

		(a)	The Vendor Representative and the
                                         Purchaser must use all reasonable endeavours to ensure that the Conditions Precedent
                                         are satisfied as expeditiously as possible and in any event on or before the End Date.

 

		(b)	The Vendor Representative and the Purchaser must each keep
                                         each other informed of the progress towards satisfaction of its obligations under clauses
                                         2.3(a).

 

		(c)	The Vendor Representative and the Purchaser must provide all
                                         reasonable assistance to each other as is necessary to satisfy the Conditions Precedent.

 

		2.4	Waiver

 

		(a)	The Conditions Precedent in sub-clauses (a) to (f) of clause
                                         2.1 may only be waived by the Purchaser, in its absolute discretion and subject to any
                                         conditions the Purchaser thinks fit to impose, by written notice to the Vendor Representative.

 

		(b)	All other Conditions Precedent
                                         (other than those referred to in subclause (a) of this clause 2.4) may only be waived
                                         by the mutual agreement of the Vendor Representative and the Purchaser.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 6

    	 	Shareholder Sale Agreement

    

 

		2.5	Termination

 

This agreement will end and the Offer will lapse
if:

 

		(a)	the Conditions Precedent are not satisfied, or waived in accordance
                                         with clause 2.4, by the End Date and:

 

		(i)	either the Purchaser gives written notice to the Vendor Representative;
                                         or

 

		(ii)	the Vendor Representative gives written notice to the Purchaser,
                                         that it wishes to end this agreement; or

 

		(b)	the Conditions Precedent become incapable of satisfaction and
                                         the parties agree that any of the Conditions Precedent cannot be satisfied.

 

		2.6	No binding agreement for
                                         transfer

 

For the avoidance of doubt, nothing in this agreement will
cause a binding agreement for the transfer of shares to arise unless and until the Conditions Precedent have been satisfied or
waived in accordance with clause 2.4 and no person will obtain rights in relation to shares as a result of this agreement unless
and until those conditions have been satisfied.

 

	3	Sale
    and Purchase

 

		3.1	Sale of Sale Shares

 

		(a)	The Purchaser offers to purchase the Sale Shares (free and
                                         clear of all Encumbrances) on the Completion Date for the Purchase Price.

 

		(b)	By completing, duly signing and returning this agreement and
                                         the Acceptance Forms, each Vendor:

 

		(i)	agrees (subject to and conditional upon Completion) to sell that
                                         Vendor’s Sale Shares to the Purchaser for the Purchase Price applicable to that
                                         Vendor’s Sale Shares, free and clear of all Encumbrances;
	 	 	 

		(ii)	warrants to the Purchaser in accordance
                                         with clause 6;
	 	 	 

		(iii)	accepts the terms and conditions
                                         contained in this agreement; and
	 	 	 

		(iii)	will have the benefit of the Purchaser Warranties and the Purchaser
                                         and Ampliphi acknowledge that the Vendors are each entering into this agreement in reliance
                                         on the Purchaser Warranties.

 

		3.2	Associated rights

 

Each Vendor who accepts the Offer must sell their
Sale Shares to the Purchaser together with all rights attached to them as at the Completion Date.

 

		3.3	Purchase Price

 

The Purchase Price consists of 40 million Consideration
Shares (subject to this agreement) being:

 

		(a)	the Completion Shares, which must be issued to the Vendors
                                         on the Completion Date;

 

		(b)	the Contingent Shares, which are part of the Consideration
                                         Shares due to the Managers (subject to this agreement) will be issued to the Escrow Agent
                                         and released to the Managers (subject to various milestones being achieved or liability
                                         claims being made) in accordance with clause 7 and Schedule 4; and

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 7

    	 	Shareholder Sale Agreement

    

 

 

		(c)	the Escrow Shares, which must be issued to the Escrow Agent
                                         and dealt with in accordance with clause 8.

 

		3.4	Consideration

 

The
consideration due to the Vendors for the Sale Shares comprises only:

 

		(a)	The Completion Shares;
	 	 	 

		(b)	The Contingent Shares; and
	 	 	 

		(c)	The Escrow Shares.

 

The
Vendors acknowledge that various restrictions apply to the Consideration Shares and to each Vendor’s right to dispose of
the Consideration Shares, as set out in Schedule 2 Parts A and B.

 

		3.5	Purchaser and Ampliphi

 

The
Purchaser must cause Ampliphi to satisfy clause 3.3.

 

		4	Completion

 

		4.1	Time and Date

 

Completion
must take place at the offices of the Company at 27 Dale Street, Brookvale, NSW 2100 at 2.00pm on the Completion Date, or at any
other place or time agreed in writing between the Company and the Purchaser.

 

		4.2	Vendors’ obligations at Completion

 

		(a)	At Completion, each of the Vendors must give to the Purchaser
                                         the following documents:

 

		(i)	share certificates for that Vendor’s Sale Shares (or an
                                         indemnity in the form reasonably required by the Purchaser in the case of any missing
                                         share certificates);

 

		(ii)	completed and executed Share Transfers in respect of that Vendor’s
                                         Sale Shares to the Purchaser, signed by the transferor;

 

		(iii)	an application to subscribe, in the form attached to this
                                         agreement as Annexure A, for the Consideration Shares to be issued to that Vendor; and

 

		(iv)	(where applicable) a completed and signed Sophisticated and
                                         Professional Investor Certificate in the form attached to this agreement as Annexure
                                         B.

 

		(b)	At Completion, the Vendors and/or the Company (as the case
                                         may be) authorise the Vendor Representative to give to the Purchaser:

 

		(i)	a copy of the Escrow Agreement duly signed by the Vendor Representative
                                         on behalf of the Vendors;

 

		(ii)	a copy of the Loan Repayment Deed duly signed by the Company
                                         and Cellabs Pty Ltd;

 

		(ii)	the Company’s minute books and statutory records;
	 	 	 

		(iii)	ledgers, journals and books of account of the Company;

 

		(iv)	cheque books of the Company and a list of all bank accounts
                                         kept by the Company;

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 8

    	 	Shareholder Sale Agreement

    

 

		(v)	a duly completed authority for the alteration of the signatories
                                         of each bank account of the Company in the same manner required by the Purchaser by written
                                         notice before the Completion Date;

 

		(vi)	a consent to act as a director, secretary or public officer
                                         from each person the Vendors wish to appoint as a director, secretary and public officer
                                         of the Purchaser (being Anthony Smithyman) and Ampliphi (being Anthony Smithyman and
                                         Tony Gellert) on and from Completion.

 

		4.3	Company board meeting

 

At
Completion, a meeting of the board of directors of the Company must be convened to approve the registration of the Purchaser as
the holder of the Sale Shares in the books of the Company, subject to the payment of Duty (if any) on the transfer of those Sale
Shares.

 

		4.4	Purchaser’s obligations at Completion

 

If
the Vendors perform their obligations in this clause 4, at Completion the Purchaser must:

 

		(a)	Issue the Completion Shares to the Vendors;

 

		(b)	Issue the Contingent Shares and Escrow Shares to the Escrow
                                         Agent as trustee;

 

		(c)	Provide a copy of the Escrow Agreement duly signed by the Purchaser,
                                         Ampliphi and the Escrow Agent to the Vendor Representative; and

 

		(d)	Provide a copy of the Loan Repayment Deed duly signed by Ampliphi
                                         to the Vendor Representative.

 

		4.5	Purchaser board meeting

 

At
or before Completion, the Purchaser must procure that a meeting of the board of directors of the Purchaser shall have been convened
to approve the issue of the Consideration Shares to the Vendors;

 

		4.6	Completion simultaneous

 

		(a)	The actions to take place as contemplated by this clause 4,
                                         are interdependent and must take place, as nearly as possible, simultaneously except
                                         for acts permitted by clause 4.5 to have taken place before Completion. If one action
                                         does not take place, then without prejudice to any rights available to any party as a
                                         consequence:

 

		(i)	there is no obligation on any party to undertake or perform any
                                         of the other actions;

 

		(ii)	to the extent that such actions have already been undertaken,
                                         the parties must do everything reasonably required to reverse those actions; and

 

		(iii)	each Vendor and the Purchaser must each return to the other
                                         all documents delivered to it under clause 4 and must each repay to the other all payments
                                         received by it under clause 4, without prejudice to any other rights any party may have
                                         in respect of that failure.

 

		(b)	The actions to take place as contemplated by this clause 4
                                         and the Managers Warranty Deed are interdependent and must take place, as nearly as possible,
                                         simultaneously, except for acts permitted by clause 4.5 of this agreement which must
                                         have taken place before Completion, if one action does not take place, then without prejudice
                                         to any rights available to any party as a consequence:

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 9

    	 	Shareholder Sale Agreement

    

 

		(i)	there is no obligation on the Purchaser to undertake or perform
                                         any of the other actions under this agreement;

 

		(ii)	to the extent that such actions have already been undertaken,
                                         the parties must do everything reasonably required to reverse those actions; and

 

		(iii)	if required by the Purchaser, each Vendor and the Purchaser
                                         must each return to the other all documents delivered to it under this clause 4 and must
                                         each repay to the other all payments received by it under this clause 4, without prejudice
                                         to any other rights any party may have in respect of that failure.

 

		(c)	The Purchaser may, in its sole discretion, waive any or all
                                         of the actions that the Vendor is required to perform under this clause 4 and the Vendor
                                         may, in its sole discretion, waive any or all of the actions that the Purchaser is required
                                         to perform under this clause 4.

 

		5	Period
                                         after Completion

 

		5.1	Exercise of rights of registered shareholder

 

		(a)	From Completion, until the Sale Shares are registered in the
                                         name of the Purchaser, each of the Vendors:

 

		(i)	hereby appoints the Purchaser as sole proxy of that Vendor to
                                         attend meetings of the Company’s shareholders and exercise the votes attached to
                                         the Sale Shares, and must not itself attend or vote at those meetings; and

 

		(ii)	shall promptly take all other actions in the capacity of a registered
                                         holder of the Sale Shares as the Purchaser directs in writing to the Vendor and at the
                                         Purchaser’s cost.

 

		6	Vendor
                                         Warranties

 

		6.1	Giving of Vendor Warranties

 

Subject
to clause 9 and the limitations in Part C of Schedule 2, by accepting the Offer, each of the Vendors gives each of the Vendor
Warranties in favour of the Purchaser and Ampliphi on the Execution Date and the Completion Date.

 

		6.2	Independent warranties

 

Each
of the Vendor’s Warranties are to be construed independently of the others and are not limited by reference to any other
Vendor Warranty, except if that limit or restriction is clearly stated in the relevant Vendor Warranty.

 

		6.3	Reliance

 

Each
of the Vendors acknowledges that the Purchaser and Ampliphi have entered into this agreement and will complete this agreement
in reliance on the Vendor Warranties.

 

		7	Manager’s
                                         Contingent Shares

 

The
Managers acknowledge that 6 million of the Consideration Shares due to each of the Managers under this agreement (12 million Consideration
Shares in total - the Contingent Shares) will be issued to, and held by, the Escrow Agent on trust from the Completion
Date. Subject to the conditions in clause 4 being met, on Completion the Purchaser must procure Ampliphi to issue the Contingent
Shares to the Escrow Agent. The Purchaser must procure the Escrow Agent to release the Contingent Shares to the Managers on the
terms contained in Schedule 4.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 10

    	 	Shareholder Sale Agreement

    

 

		8	Escrow
                                         Shares

 

		8.1	Escrow Shares

 

		(a)	On the Completion Date, and subject to the requirements in
                                         clause 4 being met, the Purchaser must procure Ampliphi to issue the Escrow Shares to
                                         the Escrow Agent.

 

		(b)	The Escrow Shares must be issued to, and held by (subject to
                                         Claims made under this agreement or the Escrow Agreement), the Escrow Agent for the period
                                         of 12 months from the Completion Date (“Escrow Period”), except
                                         that at the end of the Escrow Period, the Escrow Agent shall continue to hold Escrow
                                         Shares with a value sufficient to satisfy any Claim for which any Vendor may be liable
                                         under this agreement for which the Purchaser or Ampliphi has provided notice and which
                                         has not been resolved as of the end of the Escrow Period (“Pending Ciaim”)
                                         until the final resolution of such Pending Claim.

 

		(c)	Following the Escrow Period the Purchaser must procure the
                                         Escrow Agent to:

 

		(i)	release to each Vendor the number of Escrow Shares specified
                                         in Schedule 1 minus (A) the number of Escrow Shares that must be relinquished under clause
                                         10 to help satisfy that Vendor’s liability and (B) the number of shares described
                                         in Section 8.1(b) with respect to any Pending Claim (subject to receiving signed share
                                         transfers from each relevant Vendor in a form reasonably acceptable to the Purchaser);
                                         and

 

		(ii)	continue to hold any Escrow Shares that have a value sufficient
                                         to satisfy any Pending Claim and deal with the Escrow Shares that must be relinquished
                                         under clause 10 to help satisfy the Vendor’s liability in any manner determined
                                         by the Purchaser (at the Purchaser’s complete discretion).

 

		8.2	Escrow restrictions

 

During
the Escrow Period, the Vendors may not, and the Purchaser must procure that the Escrow Agent does not, do any of the following:

 

		(a)	dispose of, or agree or offer to dispose of, the Escrow Shares;

 

		(b)	create, or agree or offer to create, any security interest
                                         in the Escrow Shares; or

 

		(c)	do, or omit to do, any act if the act or omission would have
                                         the effect of transferring effective ownership or control of the Escrow Shares.

 

		9	Limitations
                                         of Liability

 

Except
in the case of fraud or evasion, the maximum aggregate amount recoverable by the Purchaser and/or Ampliphi (in total) from each
Vendor in relation to any Loss or Claim under or in connection with this agreement (including, but without limitation, under or
in connection with the Vendor Warranties) is the Market Value of the Escrow Shares allocated to that Vendor in Schedule 1. These
limitations will not apply to:

 

		(a)	the warranties given by a Vendor under Schedule 2, Part A paragraph
                                         1 (Title to Vendor’s Shares); or

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 11

    	 	Shareholder Sale Agreement

    

 

		(b)	the warranties given by the Managers under the Management Vendors’
                                         Warranty Deed; or

 

		(c)	legal costs of the Purchaser or Ampliphi reasonably incurred
                                         if these are ordered by a court or in a dispute resolution forum.

 

		10	Satisfaction
                                         of Claims

 

		(a)	Where a Vendor is liable under this agreement, the Vendor must
                                         relinquish (and take any other action necessary to effect this) Escrow Shares to the
                                         Purchaser in accordance with clause 10(b).

 

		(b)	For the purposes of clause 10(a) the number of Escrow Shares
                                         that must be relinquished to the Purchaser will be determined by the following formula:

 

A=
B / C

 

where:

 

A=
Number of Escrow Shares that the Vendor must relinquish to the Purchaser;

 

B=
The total liability of the Vendor in respect of the relevant Claim which is to be satisfied by the Vendor by relinquishing Escrow
Shares to the Purchaser; and

 

C=
Market Value of an Escrow Share.

 

		11	Dispute
                                         Resolution

 

		(a)	If the Purchaser and/or Ampliphi has or claims to have incurred
                                         or suffered any Loss for which it is or may be entitled to indemnification, compensation
                                         or reimbursement against a Vendor under this agreement, Ampliphi may deliver a claim
                                         notice (a “Vendor Claim Notice”) to the Vendor and to the Escrow Agent.
                                         Each Vendor Claim Notice shall be executed by an appropriate officer of Ampliphi and
                                         shall state that Ampliphi in good faith believes that there is or has been a breach of
                                         a warranty or covenant contained in this agreement or that the Purchaser and/or Ampliphi
                                         is otherwise entitled to indemnification, compensation or reimbursement under the this
                                         agreement and contain a brief description of the circumstances supporting the Ampliphi’s
                                         belief that there is or has been such a breach or that the Purchaser and/or Ampliphi
                                         is so entitled to indemnification, compensation or reimbursement and shall, to the extent
                                         possible, contain a good faith, non-binding, preliminary estimate of the amount of Loss
                                         the Purchaser and/or Ampliphi claims to have so incurred or suffered and specifically
                                         set forth the precise number of Escrow Shares to be disbursed to the Purchaser and/or
                                         Ampliphi in satisfaction of such claim (the “Vendor Claimed Amount”) and
                                         a statement that the Vendor must respond to the Vendor Claim Notice within 28 days or
                                         the Vendor Claim notice shall be deemed to be agreed.

 

		(b)	Within 28 days after providing notice to the Vendor of a Vendor
                                         Claim Notice, the Vendor may deliver to Ampliphi a written response (the “Vendor
                                         Response Notice”) in which the Vendor:

 

		(i)	agrees that a whole number of Escrow Shares, as set forth in
                                         the Vendor Claim Notice and collectively having a Market Value equal to the full Vendor
                                         Claimed Amount may be released by the Escrow Agent to Ampliphi;

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 12

    	 	Shareholder Sale Agreement

    

 

		(ii)	agrees that a whole number of Escrow Shares collectively having
                                         a Market Value equal to part, but not all, of the Vendor Claimed Amount (the “Vendor
                                         Agreed Amount”) may be released from the Escrow Account to Ampliphi; or

 

		(iii)	indicates that no part of the Vendor Claimed Amount may be
                                         released from the Escrow Account to Ampliphi. Any part of the Vendor Claimed Amount and
                                         the precise number of Vendor Escrow Shares corresponding to such Vendor Claimed Amount
                                         that is not to be released to Ampliphi shall be the “Vendor Contested Amount.”

 

If
a Vendor Response Notice is not received by Ampliphi within such 28-day period, then the Vendor Representative shall be deemed
to have agreed that Escrow Shares collectively having a Market Value equal to the full Vendor Claimed Amount shall be released
to Ampliphi by the Escrow Agent and Ampliphi may give instructions to the Escrow Agent to this effect.

 

		(c)	If the Vendor delivers a Vendor Response Notice agreeing that
                                         the number of Escrow Shares, as set forth in the Vendor Claim Notice and collectively
                                         having a Market Value equal to the full Vendor Claimed Amount may be released from the
                                         Escrow Account to Ampliphi, or if the Vendor does not deliver a Vendor Response Notice
                                         in accordance with clause 11(b), Ampliphi may instruct the Escrow Agent to promptly following
                                         the receipt of the Vendor Response Notice (or, if the Escrow Agent has not received a
                                         Vendor Response Notice, promptly following the expiration of the 28-day period referred
                                         to in clause 11(b), deliver to Ampliphi such Escrow Shares. Such payment shall be deemed
                                         to be made in full satisfaction of the claim described in such Vendor Claim Notice.

 

		(d)	If the Vendor delivers a Vendor Response Notice agreeing that
                                         Escrow Shares collectively having a Market Value equal to part, but not all, of the Vendor
                                         Claimed Amount may be released from the Escrow Account to Ampliphi, then the Vendor shall
                                         specify the precise number of Other Vendor Escrow Shares to be released in the Vendor
                                         Response Notice and Ampliphi may instruct the Escrow Agent to deliver to Ampliphi the
                                         number of Escrow Shares specified in the Vendor Response Notice that shall collectively
                                         have a Market Value equal to the Vendor Agreed Amount.

 

		(e)	If the Vendor delivers a Vendor Response Notice indicating
                                         that there is a Vendor Contested Amount, the Vendor and Ampliphi shall attempt in good
                                         faith to resolve the dispute related to the Vendor Contested Amount. If Ampliphi and
                                         the Vendor shall resolve such dispute, such resolution shall be binding on the Vendor
                                         to which the Vendor Claim Notice relates and the Purchaser and/or Ampliphi and a settlement
                                         agreement shall be signed by the Purchaser and/or Ampliphi and the Vendor and sent to
                                         the Escrow Agent, who Ampliphi may instruct to, upon receipt thereof, if applicable,
                                         release Escrow Shares from the Escrow Account in accordance with such agreement.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 13

    	 	Shareholder Sale Agreement

    

 

		(f)	If the
                                         Vendor and Ampliphi do not resolve the dispute related to the Vendor Contested Amount
                                         within 28 Business Days after the Vendor Response Notice is given (or such longer period
                                         as the Vendor and Ampliphi agree) then the dispute must be referred for resolution to
                                         an independent expert agreed by the Vendor and Ampliphi within a further 5 Business Days.
                                         If they cannot agree on who the independent expert will be within that time period, either
                                         of the Vendor and Ampliphi may request the president, at that time, of the Institute
                                         of Arbitrators and Mediators Australia (or the president’s nominee) to appoint
                                         an independent expert to resolve the dispute. The person agreed by the Vendor and Ampliphi
                                         or nominated by the Institute of Arbitrators and Mediators Australia will be the “Expert”
                                         for the purposes of this clause. The Vendor and Ampliphi must instruct the Expert
                                         to determine the dispute within the shortest practicable time, and to deliver to the
                                         Vendor and Ampliphi a report (“Expert’s Report”) which states
                                         the Expert’s decision on the dispute. The Expert will act as an expert, not as
                                         an arbitrator, in determining the dispute but should give each of the Vendor and Ampliphi
                                         an opportunity to make written submissions. The Expert’s determination must be
                                         made as soon as possible. The Expert’s decision is final, conclusive and binding
                                         (except in the case of manifest error). The parties hereto will endeavour to procure
                                         that the engagement documents for the Expert will provide for such Expert to endeavour
                                         to provide a decision within 10 Business Days of appointment, subject to delays resulting
                                         from the action or inaction of the Vendor or Ampliphi. Each party must bear its own costs
                                         in complying with this paragraph. The non-prevailing party in any arbitration shall pay
                                         the Expert’s fees and expenses. For purposes of this Section, the non-prevailing
                                         party shall be determined solely by the Expert. Any amounts payable to the Purchaser
                                         and/or Ampliphi by the Vendor shall be paid out of Shares pursuant to the written decision
                                         of the Experti.

 

		(g)	The parties agree that the Escrow Agent shall release Escrow
                                         Shares from the Escrow Account in connection with any Vendor Contested Amount within
                                         five Business Days after the delivery to it of:

 

		(i)	a copy of a settlement agreement executed by the Purchaser and/or
                                         Ampliphi and the Vendor Representative setting forth specific instructions to the Escrow
                                         Agent as to the precise number of Escrow Shares, if any, to be released from the Escrow
                                         Account, with respect to such Vendor Contested Amount and the identity of the party or
                                         parties to which such disbursement is to be made, or

 

		(ii)	a copy of the Expert’s decision referred to and as provided
                                         in clause 11(b) setting forth specific instructions to the Escrow Agent as to the number
                                         of Escrow Shares, if any, to be released from the Escrow Account, with respect to such
                                         Vendor Contested Amount,

 

and
Ampliphi must give notice to the Escrow Agent attaching copies of these documents (as soon as reasonably possible after receiving
the relevant document) to effect the content

 

		(h)	Any Escrow Shares released from the Escrow Account to the Purchaser
                                         and/or Ampliphi shall be deemed to reduce the Escrow Shares allocated to such Vendor
                                         with respect to whom the Vendor Claim Notice relates.

 

		12	Purchaser
                                         Warranties

 

		12.1	Giving of Purchaser Warranties

 

Ampliphi
and the Purchaser give the Purchaser Warranties in favour of the Vendors as at the Execution Date and as at the Completion Date
subject to the limitations in Part B of Schedule 3.

 

		12.2	Independent warranties

 

Each
of the Purchaser Warranties are to be construed independently of the others and are not limited by reference to any other Purchaser
Warranty, except if that limit or restriction is clearly stated in the relevant Purchaser Warranty.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 14

    	 	Shareholder Sale Agreement

    

 

		12.3	Reliance

 

Ampliphi
and the Purchaser acknowledge that the Vendors have accepted the Offer and will complete this agreement in reliance on the Purchaser
Warranties.

 

		11.4	Breach of Purchaser Warranty

 

If
any of the Purchaser Warranties are breached and that breach has a material adverse impact on the value of the Consideration Shares,
Ampliphi or the Purchaser (as the case may be) will be liable to pay to the relevant Vendor (subject to Ampliphi or the Purchaser
(as the case may be) receiving a written notice specifying full particulars of the Claim) the amount by which the value of the
Consideration Shares issued to that Vendor is less than would have been the case if there had no breach of the Purchaser Warranty.

 

		13	Termination

 

		13.1	Termination by the Purchaser

 

		(a)	If prior to Completion the Purchaser becomes aware of any matter
                                         which:

 

		(i)	Is a breach of any of the Vendor Warranties and such breach materially
                                         and adversely affects the total value of the Sale Shares;

 

		(ii)	Is a breach of any of the Managers’ warranties under the
                                         Management Vendors’ Warranty Deed and such breach materially and adversely affects
                                         the total value of the Sale Shares;

 

		(iii)	Is a breach of any of the Vendor obligations under clause 4
                                         in a material way; or

 

		(iv)	Is a Company Material Adverse Change,

 

then
the Purchaser may at any time before Completion terminate this agreement and withdraw the Offer by giving written notice to the
Vendor Representative. If this agreement terminates under this clause 13.1 all other rights that the Purchaser has against any
of the Vendors at law, or in equity remain unaffected, subject to clauses 1 and 9.

 

		(b)	Clause 13.1(a) does not apply if Completion cannot occur because
                                         the Purchaser is in breach of this agreement.

 

		13.2	Termination by the Vendors

 

		(a)	If prior to Completion, the Vendor Representative becomes aware
                                         of any matter which:

 

		(i)	Is a breach of any of the Purchaser Warranties and such breach
                                         materially and adversely affects the total value of the Consideration Shares; or

 

		(ii)	Is a breach by the Purchaser or Ampliphi of clause 4 in a material
                                         way; or

 

		(iii)	Is a Purchaser Material Adverse Change,

 

then
the Vendor Representative may at any time before Completion terminate this agreement by giving written notice to the Purchaser.
If this agreement terminates under this clause 13.2 all other rights that the Vendors have against the Purchaser at law, or in
equity remain unaffected.

 

		(b)	Clause 13.2(a) does not apply if the Purchaser cannot complete
                                         because the Vendors are in breach of this agreement.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 15

    	 	Shareholder Sale Agreement

    

 

		14	Confidentiality
                                         and Announcements

 

		14.1	Dictionary

 

The
following definitions apply in this clause 14.

 

Confidential
Information means any written or oral information of a technical, business or financial nature or which is taken by any
provision of this agreement to be Confidential Information, or which the Discloser makes the Recipient aware is considered by
the Discloser to be confidential and proprietary, and includes all information that is personal information for the purposes of
the Privacy Act 1988 (Cth), but does not include information which the Recipient can establish:

 

		(a)	was in the public domain when it was given to the Recipient;

 

		(b)	becomes, after being given to the Recipient, part of the public
                                         domain, except through disclosure contrary to this agreement;

 

		(c)	was in the Recipient’s possession when it was given to
                                         the Recipient and had not been acquired in some other way (directly or indirectly) from
                                         the Discloser; or

 

		(d)	was lawfully received from another person who had the unrestricted
                                         legal right to disclose that information free from any obligation to keep it confidential.

 

Discloser
means the party giving information.

 

Recipient
means the party to whom information is given.

  

14.2       Confidentiality
obligations

 

Each party must:

 

		(a)	keep the Confidential Information confidential and not disclose
                                         it or allow it to be disclosed to a third party except:

 

		(i)	with the prior written approval of the other parties; or

 

		(ii)	to officers, shareholders, employees and consultants or advisers
                                         of a party (or its related bodies corporate) who have a need to know (and only to the
                                         extent that each has a need to know) for the purposes of this agreement and are aware
                                         that the Confidential Information must be kept confidential; and

 

		(b)	take or cause to be taken reasonable precautions necessary
                                         to maintain the secrecy and confidentiality of the Confidential Information.

 

		14.3	Announcements

 

No
announcement, press release or other communication of any kind relating to the negotiations of the parties or the subject matter
or terms of this agreement must be made or authorised by or on behalf of a party without the prior written approval of each other
party, including the form and content of that disclosure, unless that announcement, press release or communication is required
to be made by law or any order of any court, tribunal, authority or regulatory body.

 

		14.4	Exceptions

 

The
obligations of confidentiality under this agreement do not extend to information (whether before or after this agreement is executed):

 

		(a)	disclosed to a party, but at the time of disclosure is rightfully
                                         known to or in the possession or control of the party and not subject to an obligation
                                         of confidentiality on the party;

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 16

    	 	Shareholder Sale Agreement

    

 

		(b)	that is public knowledge (except because of a breach of this
                                         agreement or any other obligation of confidence); or

 

		(c)	required to be disclosed by law or any order of any court,
                                         tribunal, authority or regulatory body or in connection with the enforcement of this
                                         agreement or by the rules of a recognised stock exchange.

 

		14.5	Survival

 

This
clause 14 continues despite the termination of this agreement.

 

		15	GST

 

		15.1	Definitions

 

In
this clause 15, any expression used that is defined in GST Law has the defined meaning.

 

		15.2	Consideration is GST Exclusive

 

Any
consideration to be paid or provided for a supply made under or in connection with this agreement does not include an amount of
GST (GST Exclusive Consideration).

 

		15.3	Taxable Supply

 

If
any supply by one party (Supplier) to another party (Recipient) under or in connection with this agreement
is a taxable supply, then the amount due to the Supplier for that supply will be the sum of:

 

		(a)	the GST Exclusive Consideration; and
	 	 	 

		(b)	the amount of GST payable by the Supplier in respect of that
                                         supply including any penalties or interest payable by the Supplier,

 

(the
GST Amount).

 

		15.4	Tax Invoice

 

The
Recipient’s obligation to pay to the Supplier the GST Amount is subject to the Supplier first providing to the Recipient
a tax invoice conforming with the requirements of GST Law.

 

		15.5	Penalties and Interest

 

If
a party becomes liable for any penalties or interest as a result of a late payment of GST, where that late payment is as a direct
result of a failure of another party to comply with the terms of this clause 15, that other party shall pay to the first party
an additional amount on demand equal to the amount of those penalties and interest.

 

		15.6	Reimbursement and Indemnity Payments

 

If
a payment to a party under this agreement is a reimbursement or indemnification, calculated by reference to a loss, cost or expense
incurred by that party, then the payment will be reduced by the amount of any input tax credit to which that party actually received
for that loss, cost or expense.

 

		16	Notices

 

		16.1	Form of Notice

 

Any
demand, notice, consent, approval or other communication under this agreement may be made or given by a party or the solicitor
for that party provided that it:

    	Mills Oakley Lawyers Pty Ltd ©	Page 17

    	 	Shareholder Sale Agreement

    

 

		(a)	is
                                         in legible writing, in English and addressed to the intended recipient; and

 

		(b)	is signed
                                         by the sender (if an individual) or by an authorised representative of the sender; and

 

		(c)	is
                                         given to the addressee by:

 

		(i)	delivery
                                         in person; or

 

		(ii)	post
                                         to, or leaving at, that party’s address for service; or

 

		(iii)	sending
                                         by fax to the party’s address for service; or

 

		(iv)	sending
                                         by email to the party’s email address; and

 

		(d)	is
                                         regarded as being given by the sender and received by the addressee:

 

		(i)	if by
                                         delivery in person or by being left at the party’s address for service, upon delivery;

 

		(ii)	if
                                         by post, two (2) Business Days from and including the date of posting by ordinary prepaid
                                         post in respect of an address for service within the Commonwealth of Australia and twenty
                                         one (21) Business Days in respect of other any address; or

 

		(iii)	if
                                         by fax or email, when legibly received by the addressee, with receipt being evidenced
                                         by a report generated by the sender’s machine confirming uninterrupted transmission
                                         / sending;

 

but
if the delivery or receipt occurs on a day which is not a Business Day or at a time after 5.00 pm (both the day and time being
in the place of receipt) it is regarded as having been received at 9.00am on the next following Business Day.

 

		16.2	Vendor
                                         Representative

 

		(a)	Each
                                         Vendor, by entering into this agreement, agrees to the appointment of the Vendor Representative,
                                         as provided for in this clause 15.2.

 

		(b)	Any
                                         consent or agreement or direction or waiver or notice given or made by the Vendor Representative
                                         in writing for the purposes of the agreement will be binding upon all of the Vendors.

 

		(c)	The
                                         Vendors each authorise the Vendor Representative to act on behalf of allof the
                                         Vendors in the way contemplated by this agreement and by the Escrow Agreement and to
                                         take such decisions as he shall at his entire discretion determine, and (provided the
                                         Vendor Representative acts in good faith) the Vendor Representative will have and accepts
                                         no liability to any of the Vendors nor to any other person other than the Purchaser and
                                         Ampliphi in connection with or as a result of anything which the Vendor’s Representative
                                         does, refrains from doing or neglects or omits to do in connection with any matter relating
                                         to this agreement or the Escrow Agreement.

 

		(d)	The
                                         parties acknowledge that the Vendor Representative is responsible for accepting all notices
                                         sent by the Purchaser to the Vendors as required under any provision of this agreement
                                         and under the Escrow Agreement, on behalf of the Vendors.

 

		(e)	The
                                         Vendors acknowledge that delivery to the Vendor Representative of any notices pursuant
                                         to subclause (d) constitutes delivery to the Vendors.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 18

    	 	Shareholder Sale Agreement

    

 

		16.3	Appointment
                                         of Escrow Agent

 

By
entering into this agreement, each Vendor agrees to the appointment of the Escrow Agent to hold the Escrow Shares pursuant to
the Escrow Agreement.

 

		16.4	Address
                                         for service

 

For
the purposes of this clause 16, a party’s address for service and facsimile number is:

 

	Party	 	Postal

    Address	 	Attention	 	Facsimile	 	Email
	 	 	 	 	 	 	 	 	 
	Vendor

        Representative
	 	C/o
        UBK

        Lawyers
        964

        Pacific

        Highway,

        Pymble
        NSW

        2073
	 	Dr
        Tony

        Smithyman
	 	(02)
        9391

        5577
	 	tonysmithyman@gmail.com

         

        cc
        Peter.Fairfield@fresenius-

        kabi.com

	 	 	 	 	 	 	 	 	 
	Purchaser	 	800
        E. Leigh St

        54
        Richmond,

        VA
        23219,

        United
        States

        of
        America
	 	Phil Young	 	[N/A	 	pjy@ampliphibio.com

         

        cc
        tnorgate@millsoakley.com.au

	 	 	 	 	 	 	 	 	 
	Ampliphi	 	800
        E. Leigh St

        54
        Richmond,

        VA
        23219,

        United
        States

        of
        America
	 	Phil Young	 	N/A	 	pjy@ampliphibio.com

         

        cc
        tnorgate@millsoakley.com.au

	 	 	 	 	 	 	 	 	 
	Company	 	C/o
        UBK

        Lawyers
        964

        Pacific

        Highway,

        Pymble
        NSW

        2073
	 	Dr
        Tony

        Smithyman
	 	(02)
        9391

        5577
	 	tonysmithyman@gmail.com

         

        cc
        Peter.Fairfield@fresenius-kabi.com

	 	 	 	 	 	 	 	 	 
	Vendors	 	As
        per

        Schedule
        1
	 	As
        per

        Schedule
        1
	 	N/A	 	As per
    Schedule 1

 

		17	General

 

		17.1	Further
                                         assurances

 

Each
party will promptly execute all documents and do all things that another party from time to time reasonably requires of it to
effect, perfect or complete the terms and conditions of this agreement and any transaction contemplated by it.

 

		17.2	Severability

 

If
anything in this agreement is unenforceable, illegal or void then it is severed and the rest of this agreement remains in force.

 

		17.3	Non-merger
                                         of provisions

 

A
provision of this agreement which can and is intended to operate after its conclusion will remain in full force and effect.

 

		17.4	Waiver

 

		(a)	A single
                                         or partial exercise or waiver of a right relating to this agreement will not prevent
                                         any other exercise of that right or the exercise of any other right

 

		(b)	A party
                                         will not be liable for any loss, cost or expense of any other party caused or contributed
                                         to by any waiver, exercise, attempted exercise or failure to exercise, or any delay in
                                         the exercise of, a right.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 19

    	 	Shareholder Sale Agreement

    

 

		17.5	Entire
                                         agreement

 

This
agreement embodies the entire agreement and understanding between the parties concerning its subject matter and succeeds and cancels
all other agreements and understandings concerning the subject matter of this agreement and any warranty, representation, guarantee
or other term and condition of any nature not contained in this agreement is of no force or effect.

 

		17.6	No
                                         amendments without agreement

 

This
agreement may not be modified, discharged or abandoned unless by a document signed by the parties.

 

		17.7	Assignment

 

The
rights and obligations of each party under this agreement are personal. No party may assign, encumber or otherwise deal with such
rights and obligations without the prior written consent of all other parties.

 

		17.8	Costs,
                                         expenses and stamp duty

 

		(a)	Each
                                         party must bear its own costs and expenses arising out of and in connection with the
                                         negotiation, preparation and execution of this agreement.

 

		(b)	All
                                         stamp duty (including fines, penalties and interest) which may be payable on or in connection
                                         with this agreement and any instrument executed under this agreement must be borne by
                                         the Purchaser.

 

		(c)	All
                                         costs of the Escrow Agent must be borne by the Purchaser.

 

		17.9	Counterparts

 

		(a)	This
                                         agreement may consist of a number of counterparts and, if so, the counterparts taken
                                         together constitute one and the same instrument.

 

		(b)	This
                                         agreement is not binding on any party unless one or more counterparts have been duly
                                         executed by, or on behalf of, each person named as a party to this agreement and those
                                         counterparts have been exchanged.

 

		(c)	A
                                         copy of a counterpart sent by facsimile machineor emailed as a PDF:

 

		(i)	must
                                         be treated as an original counterpart;

 

		(ii)	is
                                         sufficient evidence of the execution of the original; and

 

		(iii)	may
                                         be produced in evidence for all purposes in place of the original.

 

		17.10	Jurisdiction

 

This
agreement is to be governed by and construed in accordance with all applicable laws in force in the State from time to time and
the parties submit to the non-exclusive jurisdiction of the courts of the State.

 

		17.11	Attorneys

 

Where
this agreement is executed on behalf of a party by an attorney, that attorney by executing this agreement declares and warrants
that he or she:

 

		(a)	has
                                         been duly appointed; and

 

		(b)	has
                                         no notice of the power of attorney under the authority of which he or she executes the
                                         agreement having been revoked.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 20

    	 	Shareholder Sale Agreement

    

 

	
	 

 

		Schedule 1	Vendors,
                                         Sale Shares and Consideration

 

SPECIAL
PHAGE HOLDINGS PTY LIMITED

A.C.N.
102 575 511

 

	Contact	 	Shareholder
    Full Name & Address	 	Sale
    Shares

    (SPH Shares)	 	Total

    Consideration

    Shares	 	Escrow

    Shares	 	Completion

    Consideration	 	Contingency

    Shares
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dr
    Tony Smithyman	 	Anthony
        M Smithyman

        14
        Norfolk Avenue

        Collaroy
        NSW 2097

        tonysmithyman@gmail.com

        Ph:
        02 9982 5613

        Mob:
        0419 291 190
	 	6,000,000	 	10,570,149	 	2,114,030	 	2,456,119	 	6,000,000
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dr Tony Smithyman	 	Margaret
        Smithyman

        14 Norfolk
        Avenue

        Collaroy
        NSW 2097

        margotsmithyman@gmail.com

        Ph: 02 9982
        5613
	 	6,750,000	 	11,891,417	 	2,378,283	 	3,513,134	 	6,000,000
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dr
    Tony Smithyman	 	Dr
        & Mrs A Smithyman

        PO
        Box 421

        Brookvale
        NSW 2100

        tonysmithyman@gmail.com

        Ph:
        02 9982 5613
	 	500,000	 	880,846	 	176,169	 	704,677	 	N/A

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 21

    	 	Shareholder Sale Agreement

    

 

	
	 

 

	Contact	 	Shareholder
    Full Name & Address	 	Sale
    Shares

    (SPH Shares)	 	Total

    Consideration

    Shares	 	Escrow

    Shares	 	Completion

    Consideration	 	Contingency

    Shares
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    & Mrs D Crease	 	Doug
        & Jean Crease atf Doug & Jean

        Crease
        Super Fund

        5/14
        Kurraba Road

        Neutral
        Bay NSW 2089

        doug@creasepartners.com.au

        Ph:
        02 9460 0711

        Mobile:
        0410 425 124
	 	762,500	 	1,343,290	 	268,658	 	1,074,632	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Tony Gellert	 	APG
        Nominees Pty Ltd atf AP Gellert

        Family
        Trust

        38
        Owen Street

        Lindfield
        NSW 2070

        tgellert@bigpond.com

        Ph:
        02 9880 771

        Mob:
        0402 333 363
	 	950,000	 	1,673,607	 	334,721	 	1,338,885	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Tony Gellert	 	APG Nominees
        Pty Ltd atf The AP

        Gellert
        Superannuation Fund

        38 Owen
        Street

        Lindfield
        NSW 2070

        tgellert@bigpond.com

        Ph: 02 9880
        771

        Mob: 0402 333 363
	 	750,000	 	1,321,269	 	264,254	 	1,057,015	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    David Thompson	 	Camdare
        Pty Ltd

        57 Braeside
        Street

        Wahroonga
        NSW 2076

        dcthom1@attglobal.net

        Mob: 0408
        216 713
	 	750,000	 	1,321,269	 	264,254	 	1,057,015	 	N/A

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 22

    	 	Shareholder Sale Agreement

    

 

	
	 

 

	Contact	 	Shareholder
    Full Name & Address	 	Sale
    Shares

    (SPH Shares)	 	Total

    Consideration

    Shares	 	Escrow

    Shares	 	Completion

        Consideration
	 	Contingency

    Shares
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr Michael Flannery	 	Gabodi
Pty Ltd 

C/- Instigo

Lvl
        8, 217 Clarence St

Sydney
        NSW 2000

        michael@instigo.com.au 

        Ph:
        02 9248 2611
	 	250,000	 	440,423	 	88,085	 	352,338	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dr
    David Hale	 	Maxivend
        Pty Ltd atf David Hale

        Super
        Fund

        9
        Blenheim Road

        Lindfield
        NSW 2070

        drdghale@hotmail.com

        Mob:
        0407 464 841
	 	250,000	 	440,423	 	88,085	 	352,338	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dr
    G H Rajasekariah	 	Biofirm
        Pty Ltd

        18
        Burraneer Avenue

        St
        Ives NSW 2075

        raj@cellabs.com.au

        Ph:
        02 9402 5587

        Mob:
        0434 035 774
	 	225,000	 	396,381	 	79,276	 	317,104	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Neil Pickup	 	Arapahoe
        Pty Ltd

        PO
        Box 206

        Balgowlah
        NSW 2093

        neil@ovationtravel.com.au

        Mob:
        0449 935 040
	 	625,000	 	1,101,057	 	220,211	 	880,846	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Grant Symes	 	Shigetsugu
        Pty Ltd atf G Symes

        Superfund

        PO Box 264

        Hornsby
        NSW 1630

        gsymes@russellsymes.com.au

        Ph: 02 9476
        6356

        Mob: 0411
        752 231
	 	350,000	 	616,592	 	123,318	 	493,274	 	N/A

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 23

    	 	Shareholder Sale Agreement

    

 

	
	 

 

	Contact	 	Shareholder
    Full Name & Address	 	Sale
    Shares

    (SPH Shares)	 	Total

    Consideration

    Shares	 	Escrow

    Shares	 	Completion

    Consideration	 	Contingency

    Shares
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Andrew Sneddon	 	Jalba
        Pty Ltd

        12
        Mason Ave,

        Cheltenham
        NSW 2119

        asneddon@jalba.com.au

        Ph:
        02 9876 2863

        Mob:
        0418 292 490
	 	375,000	 	660,634	 	132,127	 	528,507	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Pierre Saliba	 	Pierre
        Issa Saliba

        Gribbyvagen
        100

        163
        55 Spanga, Stockholm

        Sweden

        stream
        away@hotmail.com

        Total
	 	500,000	 	880,846	 	176,169	 	704,677	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Warren Dick	 	Warren
        J Dick

        C/-
        Price Waterhouse Coopers

        201
        Sussex Street

        Sydney
        NSW 2000

        warren.dick@au.pwc.com

        Ph:
        02 8286 2935

        Mob:
        0419 479 279
	 	50,000	 	88,085	 	17,617	 	70,468	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mrs
    Lynda Preston	 	TCS
        Biosciences Ltd

        Botolph
        House

        Botolph
        Claydon

        Buckhinghamshire
        MK18 2LR

        United
        Kingdom

        Iynda.preston@tcsgroup.co.uk

        Ph:
        + 44 1296 714 222
	 	250,000	 	440,423	 	88,085	 	352,338	 	N/A

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 24

    	 	Shareholder Sale Agreement

    

 

	
	 

 

	Contact	 	Shareholder
    Full Name & Address	 	Sale
    Shares

    (SPH Shares)	 	Total

    Consideration

    Shares	 	Escrow

    Shares	 	Completion

    Consideration	 	Contingency

    Shares
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr Alastair Winter	 	Alastair
                                    Winter

                                    55 Half Moon Lane

                                    Dulwich London SE24 9JX

        United
        Kingdom

        alastair.winter@danielstewart.co.uk

        Ph:
        +44 793 9265947
	 	250,000	 	440,423	 	88,085	 	352,338	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Alastair Winter	 	Argyle
                                    Europe Limited

        55
        Half Moon Lane

        Dulwich
        London SE24 9JX

        United
        Kingdom

        alastair.winter@danielstewart.co.uk

        Ph:
        +44 793 9265947
	 	225,000	 	396,381	 	79,276	 	317,104	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Ms
    Anita Hibbert	 	Anita
                                    Hibbert

        55
        Half Moon Lane

        Dulwich
        London

        SE24
        9JX

        United
        Kingdom

        anitachibbert@googlemail.com

        Ph:
        +44 7939 265947
	 	50,000	 	88,085	 	17,617	 	70,468	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Howard Wigham	 	Howard
                                    Wigham 

                                    C/- Steve Sherwood

                                    49 Clifton Road,

        Clovelly
        NSW 2031

        stevesherwood@bigpond.com

        Total
	 	150,000	 	264,254	 	52,851	 	211,403	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Howard Wigham	 	Girby
                                    Corporation Pty Ltd atf

        Wigham
        Family Trust

        C/-
        Steve Sherwood

        49
        Clifton Road,

        Clovelly
        NSW 2031

        stevesherwood@bigpond.com

        Total 

        
	 	50,000	 	88,085	 	17,617	 	70,468	 	N/A

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 25

    	 	Shareholder Sale Agreement

    

 

	
	 

 

	Contact	 	Shareholder
    Full Name & Address	 	Sale
    Shares

    (SPH Shares)	 	Total

    Consideration

    Shares	 	Escrow

    Shares	 	Completion

    Consideration	 	Contingency

    Shares
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Hugh Hurst	 	Hugh
        Hurst

        60
        Elms Road

        Clapham
        London SW4 9EW

        United
        Kingdom

        Hurst.hughe@gmail.com

        Ph:
        +44 020 7622 5807
	 	62,500	 	110,106	 	22,021	 	88,085	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mrs
    Colleen Black	 	Colleen
        Black

        5
        Lakeview Parade

        Warriewood
        NSW 2102

        acquaries@optusnet.com.au

        Mob:
        0413 306 483
	 	120,000	 	211,403	 	42,281	 	169,122	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Andrew Hibbert	 	Andrew
        Hibbert

        3
        bis rue du General Delanne 92200

        Nueilly-sur-Seine,

        France

        andrewhibbert@gmail.com

        Ph:
        +33 67 494 7461
	 	439,000	 	773,383	 	154,677	 	618,706	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Craig Lawn	 	Craig
        Lawn

        14
        The Promedade,

        Cheltenham
NSW 2119 

        craig.s.lawn@au.Dwc.com 

        Mob:
        0419 278 254
	 	125,000	 	220,211	 	44,042	 	176,169	 	N/A

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 26

    	 	Shareholder Sale Agreement

    

 

	
	 

 

	Contact	 	Shareholder
    Full Name & Address	 	Sale
    Shares

    (SPH Shares)	 	Total

    Consideration

    Shares	 	Escrow

    Shares	 	Completion

    Consideration	 	Contingency

    Shares
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Colonel
Samuel K Martin	 	Col.
Samuel Martin 

2916 Cabin Creek Drive

Burtonsville
        MD 20866

        United
States of America 

        njuma@aol.com

        Ph:
        +1 301 384 3017
	 	62,500	 	110,106	 	22,021	 	88,085	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Wayne Hughes	 	Wayne Hughes

        22 Marina
        Road

        Elanora
        Heights NSW 2101

        whughes@businessperceptions.com.au

        Mob: 0419
        707 022
	 	50,000	 	88,085	 	17,617	 	70,468	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Giles Hamilton	 	Giles Hamilton

        Meiklerig
        Stenton

        East Lothian.
        Scotland. EH42 1 TF

        United Kingdom

        giles.hamilton@gmail.com 

        Ph: +44
        797 1046605
	 	50,000	 	88,085	 	17,617	 	70,468	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Peter Downes	 	Peter Downes

        77 Riviera
        Avenue

        Avalon NSW
2107 

        peter@peterdownes.com

        Ph: 02 9973
        3312
	 	50,000	 	88,085	 	17,617	 	70,468	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    John Batty	 	John
        Batty

        1
        The Spinney

        Bakers
        Hill Hadley Common

        Barnet
        Hertfordshire EN5 5QJ

        United
        Kingdom

        jcrbbatty@btinternet.com

        

        Ph:
+44 208 441 8939 

Mob: +44 7515 061 280
	 	137,500 	 	242,233	 	48,447	 	193,786	 	N/A

   

    	Mills Oakley Lawyers Pty Ltd ©	Page 27

    	 	Shareholder Sale Agreement

    

 

	
	 

 

	Contact	 	Shareholder
    Full Name & Address	 	Sale
    Shares

    (SPH Shares)	 	Total

    Consideration

    Shares	 	Escrow

    Shares	 	Completion

    Consideration	 	Contingency

    Shares
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Craig Wood	 	Glowcave
        Pty Ltd atf Wood Super Fund

        RBS
        Morgans

        Lvl
        2 341 Barrenjoey Rd

        Newport
        NSW 2106

        cwood@rbsmorgans.com

        Ph:
        02 9998 4210

        Mob:
        0419 218 565
	 	62,500	 	110,106	 	22,021	 	88,085	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Colin Gair	 	Wheeler
        Superannuation Pty Ltd

        Suite
        237/117 Old Pittwater Road,

        Brookvale
        NSW 2100

        Colin@wheeleraccounting.com.au

        Mob:
        0412 556 695
	 	50,000	 	88,085	 	17,617	 	70,468	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Mervyn Chappel	 	Mervyn Hylton
        Chappel & Anne

        Muriel Chappel
        atf M & A Chappel

        Superfund

        PO
Box 2339 Kent Town SA 5071 

        mervchap@bigpond.net.au

        Ph: 08 8364
        5337

        Mob: 0419
        866 810
	 	100,000	 	176,169	 	35,234	 	140,935	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 28

    	 	Shareholder Sale Agreement

    

 

	Share Sale Agreement
	 

 

	Contact	 	Shareholder
    Full Name & Address	 	Sale
        Shares

        (SPH
        Shares)
	 	Total

        Consideration

        Shares
	 	Escrow

        Shares
	 	Completion

        Consideration
	 	Contingency

        Shares

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Richard Hiam	 	Richard
Hiam 

Chase Cottage 

Oak Grange Road

West
        Clandon Surrey

        GU4
        7UB United Kingdom

        richard
        hiam@hotmail.com

        Ph:
        +44 1483 223344

        Mob:
        +44 7901 711553
	 	108,952	 	191,940	 	38,388	 	153,552	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dr
    & Mrs H Mazure	 	Hubert
        & Hestanne Mazure atf

        Mazure
        Family Superannuation Fund

        63
        Rebecca Parade

        Winston
Hills NSW 2153 

        humazure@hotmail.com

        Ph:
        02 9674 2607

        Mob:
        0404 199 146
	 	150,000	 	264,254	 	52,851	 	211,403	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Mark Kiss	 	Flying
        Bricks Holdings Pty Ltd atf

        Flying
        Bricks Super Fund

        PO
        Box 4218

        Castlecrag
        NSW 2068

        mkiss@psvl.com.au

        Mob:
        00412 903 389
	 	75,000	 	132,127	 	26,425	 	105,701	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Ms
    Susan Wilcox	 	Ms
        Susan Louise Wilcox & Ms

        Catherine
        Antonia Williams atf

        Williams
        Super Fund

        4/207
        Ocean Street,

        Narrabeen
        NSW 2101

        suewilcox@tpg.com.au

        Mob:
        0422 217 051
	 	50,000	 	88,085	 	17,617	 	70,468	 	N/A

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 29

    	 	Shareholder Sale Agreement

    

 

	Share Sale Agreement
	 

 

	Contact	 	Shareholder
    Full Name & Address	 	Sale
    Shares

    (SPH Shares)	 	Total

    Consideration

    Shares	 	Escrow

    Shares	 	Completion

    Consideration	 	Contingency

    Shares
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dr Bernard Hudson	 	Dr
                                    Bernard Joseph Hudson

                                    PO Box 905

        Balgowlah

        NSW
        2093

        berniehudson@masta.edu.au

        Mob:
        0414 495 448
	 	125,000	 	220,211	 	44,042	 	176,169	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mr
    Derek Johanson	 	Teesdale
                                    Holdings Pty Ltd atf

        Johanson
        Superfund

        PO
        Box 175

        Collaroy
        NSW 2097

        Ph:
        02 9981 2333

        johd@ozemail.com.au

        Ph:
        02 9981 2333
	 	75,000	 	132,127	 	26,425	 	105,701	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dr
    Tony Smithyman	 	Anthony
                                    M Smithyman

        ATF
        Staff Share Scheme

        C/-14
        Norfolk Avenue

        Collaroy
        NSW 2097

        tonysmithyman@gmail.com

        Ph:
        02 9982 5613

        Mob:
        0419 291 190
	 	750,000	 	1,321,269	 	264,254	 	1,057,015	 	N/A
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total	 	 	 	 	 	40,000,000	 	8,000,000	 	20,000,000	 	12,000,000
	Total	 	 	 	22,705,452	 	40,000,000	 	 	 	 	 	 

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 30

    	 	Shareholder Sale Agreement

    

 

		Schedule 2	Vendor
                                         Warranties

 

PART
A: VENDOR WARRANTIES

 

		1.	Title

 

At
Completion:

 

		(a)	the Vendor is the legal and beneficial
                                         owner of those Sale Shares which are listed next to the Vendor’s name in Schedule
                                         1 (“Vendor’s Shares”), these constitute the complete equity
                                         interest of the Vendor in the Company and the Vendor’s Shares are free of any Encumbrance;

 

		(b)	the Purchaser will acquire the full legal and beneficial ownership
                                         of the Vendor’s Shares free and clear of all Encumbrances, subject to registration
                                         of the Purchaser in the register of shareholders;

 

		(c)	the Vendor’s Shares are fully
                                         paid up; and

 

		(d)	subject to any express terms of this agreement, the Vendor
                                         is entitled to sell, assign and transfer the full legal and beneficial ownership of the
                                         Vendor’s Shares to the Purchaser on the terms set out in this agreement (without
                                         restriction).

 

		2.	Power

 

		(a)	The execution, delivery and performance by the Vendor of any
                                         forms and documents required to accept the Offer, transfer the Vendor’s Shares
                                         and be issued with Consideration Shares:

 

		(i)	complies with the Vendor’s constitution or other constituent
                                         documents (if a corporate entity); and

 

		(ii)	does not constitute a breach of any law or obligation, or cause
                                         or result in a default under any agreement, or Encumbrance, by which the Vendor is bound
                                         and that would prevent the Vendor from entering into and performing their obligations
                                         under this agreement.

 

		(b)	All necessary authorisations for the execution, delivery and
                                         performance by the Vendor of the forms and documents referred to in clause 2(a) of this
                                         Schedule have been obtained or will be obtained before Completion.

 

		(c)	The Vendor has full power and capacity
                                         to own its own assets and to enter into and perform its obligations under this agreement.

 

		(d)	The Vendor (if a corporate entity)
                                         is validly incorporated, organised and subsisting in accordance with the laws of its
                                         place of incorporation.

 

		(e)	The Vendor’s obligations under
                                         this agreement are enforceable in accordance with its terms.

 

		3.	Securities Law Warranties

 

		(a)	Purchase Entirely for Own Account.
                                         The Consideration Shares to be received by each Vendor are being acquired for such Vendor’s
                                         own account not as a nominee or agent, and not with a view to the resale or distribution
                                         of any part thereof, and that such Vendor has no present intention of selling, granting
                                         any participation in, or otherwise distributing the same. The acquisition by each Vendor
                                         of any of the Consideration Shares shall constitute confirmation of the representation
                                         by each such Vendor that such Vendor does not have any contract, undertaking, agreement
                                         or arrangement with any person to sell, transfer or grant participations to such person
                                         or to any third person, with respect to any of the Consideration Shares.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 31

    	 	Shareholder Sale Agreement

    

 

		(b)	Disclosure of Information. Each Vendor believes that it has
                                         received from the directors of the Company that information that the Vendor considers
                                         necessary or appropriate for deciding whether to sell their Sale Shares and acquire the
                                         Consideration Shares as contemplated by this agreement. Each Vendor further represents
                                         that it has had an opportunity to ask questions and receive answers from the directors
                                         of the Company regarding the transactions contemplated by this agreement.

 

		(c)	Investment Experience. Each Vendor
                                         acknowledges that it is able to fend for itself, can bear the economic risk of its investment,
                                         and has such knowledge and experience in financial or business matters that it is capable
                                         of evaluating the merits and risks of acquiring the Consideration Shares. Each Vendor
                                         acknowledges that any acquisition of Consideration Shares involves a high degree of risk,
                                         and represents that it is able, without materially impairing its financial condition,
                                         to hold the Consideration Shares for an indefinite period of time and to suffer a complete
                                         loss of its investment.

 

		(d)	Accredited Investor; Non-U.S. Persons. Each Vendor, certifying
                                         on its own behalf, either:

 

		(A)	is an “accredited investor”
                                         within the meaning of Securities and Exchange Commission (“SEC”)
                                         Rule 501 of Regulation D, as presently in effect; or

 

		(B)	(i)	certifies that such
                                         Vendor is not a “U.S. person” within the meaning of SEC Rule 902 of Regulation
                                         S, as presently in effect, and that such Vendor is not acquiring the Consideration Shares
                                         for the account or benefit of any such U.S. person,

 

		(ii)	agrees to resell the Consideration Shares only in accordance
                                         with the provisions of Regulation S, pursuant to registration under the US Securities
                                         Act, or pursuant to an available exemption from registration and agrees not to engage
                                         in hedging transactions with regard to such Consideration Shares unless in compliance
                                         with the US Securities Act,

 

		(iii)	agrees that any certificates for any Consideration Shares
                                         issued to such Vendor shall contain a legend to the effect that transfer is prohibited
                                         except in accordance with the provisions of Regulation S, pursuant to registration under
                                         the US Securities Act or pursuant to an available exemption from registration and that
                                         hedging transactions involving such Consideration Shares may not be conducted unless
                                         in compliance with the US Securities Act,

 

		(iv)	agrees that Ampliphi is hereby required to refuse to register
                                         any transfer of any Consideration Shares issued to such Vendor not made in accordance
                                         with the provisions of Regulation S, pursuant to registration under the US Securities
                                         Act, or pursuant to an available exemption from registration.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 32

    	 	Shareholder Sale Agreement

    

 

PART
B: VENDOR ACKNOWLEDGEMENTS

 

		(a)	Restricted Securities. Each
                                         Vendor understands that the Consideration Shares it is acquiring are characterized as
                                         “restricted securities” under the US federal securities laws inasmuch as
                                         they are being acquired from Ampliphi in a transaction not involving a public offering
                                         and that under such laws and applicable regulations such securities may be resold without
                                         registration under the US Securities Act only in certain limited circumstances. In this
                                         connection, such Vendor represents that it is familiar with SEC Rule 144, as presently
                                         in effect, and understands the resale limitations imposed thereby and by the US Securities
                                         Act. Such Vendor understands that the Consideration Shares have not been and will not
                                         be registered under the US Securities Act and have not been and will not be registered
                                         or qualified in any state in which they are offered, and thus the Vendor will not be
                                         able to resell or otherwise transfer his, her or its Consideration Shares unless they
                                         are registered under the US Securities Act and registered or qualified under applicable
                                         state securities laws, or an exemption from such registration or qualification is available.

 

		(b)	Further Limitations on Disposition. Without in any way
                                         limiting the representations set forth above, each Vendor further agrees not to make
                                         any disposition of all or any portion of the Consideration Shares unless and until the
                                         conditions of both (i) and (ii) have been met:

 

		(i)	Either of the following (a) or (b):

 

		(A)	There is then in effect a registration statement under the
                                         US Securities Act covering such proposed disposition and such disposition is made in
                                         accordance with such registration statement; or

 

		(B)	(A) Such Vendor shall have notified Ampliphi of the proposed
                                         disposition and shall have furnished Ampliphi with a detailed statement of the circumstances
                                         surrounding the proposed disposition, and (B) if reasonably requested by the Ampliphi
                                         (or its agents), such Vendor shall have furnished Ampliphi (or its agents) with an opinion
                                         of counsel reasonably satisfactory to Ampliphi (or such agents) that such disposition
                                         will not require registration of such shares under the US Securities Act; and

 

		(ii)	The transferee has agreed in writing to be bound to the terms
                                         of this Part B, pertaining to the restrictions and requirements of the US Securities
                                         Act, including, without limitation, transfer restrictions and legend requirements under
                                         Regulation S, provided that such agreement to be bound shall not be required by a transferee
                                         if Ampliphi (or its agents) are furnished with an opinion of counsel reasonably satisfactory
                                         to Ampliphi that (a) the certificates representing Purchaser Shares would, when transferred
                                         to the transferee, no longer be required to bear the applicable legends set forth below
                                         in this Part B, and (b) the transfer restrictions to which such legends relate would
                                         not apply to the Purchaser Shares when held by the transferee.

 

		(c)	Legends. It is understood by the Vendors that the certificates
                                         evidencing the Consideration Shares will bear the following legends:

 

		(i)	If the Vendor is an “accredited investor” within
                                         the meaning of Securities and Exchange Commission (“SEC”) Rule 501 of Regulation
                                         D, as presently in effect:

 

		(ii)	“THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED
                                         STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD,
                                         OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT
                                         IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR AN OPINION OF COUNSEL SATISFACTORY
                                         TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO RULE
                                         144 OF SUCH ACT.”

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 33

    	 	Shareholder Sale Agreement

    

 

		(iii)	if the Vendor is not an “accredited investor” and
                                         is otherwise not a “U.S. person” within the meaning of SEC Rule 902 of Regulation
                                         S, as presently in effect:

 

		(iv)	“THE SECURITIES REPRESENTED HEREBY HAVE BEEN OFFERED IN
                                         AN OFFSHORE TRANSACTION TO A PERSON WHO IS NOT A U.S. PERSON (AS DEFINED HEREIN) PURSUANT
                                         TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”).”

 

		(v)	“THE TRANSFER OF THESE SECURITIES IS PROHIBITED EXCEPT IN ACCORDANCE
                                         WITH THE PROVISIONS OF REGULATION S AS PROMULGATED BY THE UNITED STATES SECURITIES AND
                                         EXCHANGE COMMISSION UNDER THE ACT, PURSUANT TO REGISTRATION UNDER THE ACT, OR PURSUANT
                                         TO AN AVAILABLE EXEMPTION FROM REGISTRATION, AND HEDGING TRANSACTIONS INVOLVING THESE
                                         SECURITIES (INCLUDING ANY SWAP OR ANY OTHER AGREEMENT OR ANY TRANSACTION THAT TRANSFERS,
                                         IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, THE ECONOMIC CONSEQUENCE OF OWNERSHIP OF
                                         THESE SECURITIES, WHETHER ANY SUCH SWAP, AGREEMENT OR TRANSACTION IS TO BE SETTLED BY
                                         DELIVERY OF ALL OR ANY PORTION OF THESE SECURITIES OR ANY OTHER SECURITIES, IN CASH OR
                                         OTHERWISE), MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE ACT. “UNITED STATES”
                                         AND “U.S. PERSON” ARE AS DEFINED BY REGULATION S UNDER THE ACT.”

 

		(vi)	Any legends otherwise required by applicable securities laws.

 

PART C: LIMITATIONS

 

		1.	Time Limits

 

A
Vendor shall not be liable for any Vendor Claim unless the Purchaser gives written notice of the Vendor Claim to that Vendor or
to the Vendor Representative (containing reasonable details of the nature of the Vendor Claim), within 12 months of the Completion
Date.

 

		2,	Withdrawal

 

Any
Vendor Claim shall (if it has not been previously satisfied, settled or withdrawn) be deemed to have been withdrawn unless legal
proceedings in respect of it or other dispute resolution proceeding (such as those outlined in clause 11 or Schedule 4) have been
commenced by both being issued and served within 6 months after notice has been given by the Purchaser to the Vendor or to the
Vendor Representative, except where the Vendor Claim relates to a contingent liability in which case it shall be deemed to have
been withdrawn unless legal proceedings in respect of it have been commenced by being both issued and served within 6 months of
it having become an actual liability.

 

		4.	Maximum Liability

 

The
maximum aggregate liability of a Vendor for any Vendor Claims is set out in clause 9.

 

		5.	Acts or Omissions of the Purchaser

 

A
Vendor will not be liable for any Vendor Claim which would not have arisen but for any voluntary act, omission or transaction
carried out:

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 34

    	 	Shareholder Sale Agreement

    

 

		(a)	after the date of this agreement by
                                         the Purchaser or Ampliphi; or

 

		(b)	before Completion by the Vendor at the
                                         written direction or request of the Purchaser or Ampliphi or any affiliate of Ampliphi,

 

and
which, in any such case, the Purchaser, or Ampliphi or affiliate (as the case may be) was actually aware or ought reasonably to
have been aware that such act, omission or transaction would give or is likely to give rise to the Vendor Ciaim in question.

 

		6.	Duty to Mitigate

 

Nothing
in this Part C of Schedule 2 shall restrict or limit the general obligation at law of the Purchaser and Ampliphi to mitigate any
Loss which it may suffer in consequence of any breach by a Vendor of any of the Vendor Warranties.

 

		7.	Conduct of Claims

 

If
the Purchaser or Ampliphi become aware of any claim by a third party which might reasonably be expected to result in a Vendor
Claim being made (a “Third Party Claim”), the Purchaser and Ampliphi (as the case may be) must:

 

		(a)	within 20 Business Days of becoming
                                         aware of it, give written notice of such Third Party Claim to the Vendor containing such
                                         details of the Third Party Claim as the Purchaser has available to it, but so that any
                                         failure by the Purchaser or Ampliphi to give such notice within such period shall not
                                         prejudice the right of the Purchaser or Ampliphi to make a Claim in relation to such
                                         Third Party Claim;

 

		(b)	not make any admission of liability,
                                         agreement or compromise to or with any person in relation to that Third Party Claim without
                                         the prior written consent of the Vendor connected with the Third Party Claim (Affected
                                         Vendor) (such consent not to be unreasonably withheld or delayed); and

 

		(c)	subject to it being indemnified to its
                                         reasonable satisfaction by the Affected Vendor against all Loss incurred in respect of
                                         that Third Party Claim take such action as the Affected Vendor may reasonably request
                                         to avoid, resist, dispute, appeal, compromise or defend such Third Party Claim.

 

		8.	Recovery From Third Parties

 

If
a Vendor makes any payment to the Purchaser or Ampliphi in relation to a Vendor Claim (the “Damages Payment”) and
the Purchaser or Ampliphi receives any sum or benefit otherwise than from the Vendor (whether by payment, discount, credit, relief
or otherwise, and including from any Tax authority) which would not have been received but for the circumstances giving rise to
that Vendor Claim, then the Purchaser or Ampliphi must (once the sum or benefit has been received) immediately repay to the Vendor
an amount equal to such sum or benefit (net of taxation on that amount and reasonable costs of recovery) or, if less, the Damages
Payment.

 

		9.	Changes in Law, Tax Rates and Accounting
                                         Policies

 

A
Vendor will not be liable for any Vendor Claim if and to the extent that it is attributable to or the amount of such Vendor Claim
is increased as a result of:

 

		(a)	any legislation not in force at the
                                         date of this agreement;

 

		(b)	any change of law, regulation, directive,
                                         requirement or administration practice which takes effect retroactively; or

 

		(c)	any change in the rates of tax in force
                                         at the date of this agreement.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 35

    	 	Shareholder Sale Agreement

    

 

		10.	No Double Recovery

 

Neither
the Purchaser nor Ampliphi will be entitled to recover damages or obtain payment, reimbursement, restitution or indemnity:

 

		(a)	more than once in respect of any one liability, loss or breach
                                         or other set of circumstances which give rise to more than one Vendor Claim; or

 

		(b)	if damages, payment, reimbursement, restitution or indemnity
                                         has already been made or paid in respect of that liability, loss or breach or set of
                                         circumstances to any member of Ampliphi’s Group.

 

		11.	General

 

		(a)	A Vendor will not be liable for a Vendor
                                         Claim if and to the extent that the fact, matter, event or circumstance giving rise to
                                         such Vendor Claim was Disclosed in the Vendor Disclosure Letter.

 

		(b)	A Vendor will not be liable in respect
                                         of any Vendor Claim where the liability which is the subject matter of such Vendor Claim
                                         is contingent only, unless and until such contingent liability becomes an actual liability
                                         and is due and payable.

 

DEFINITIONS

 

In
this Schedule 2, unless the context requires otherwise

 

“Ampliphi’s
Group” means Ampliphi, Biocontrol Limited, the Purchaser and any subsidiary of Ampliphi.

 

“Disclosed”
means fairly disclosed in the Manager’s Disclosure Letter with sufficient detail to allow the recipient to make an informed
assessment of the nature and scope of the matters, facts and circumstances disclosed.

 

“Vendor
Claim” means any claim against a Vendor for breach by that Vendor of the Vendor Warranties.

 

“Vendor
Disclosure Letter” means the disclosure letter dated on or about the date of this agreement from the Vendor Representative
to Ampliphi and the Purchaser.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 36

    	 	Shareholder Sale Agreement

    

 

		Schedule 3	Purchaser
                                         Warranties

 

PART
A: Purchaser Warranties

 

		1.	Organization, Standing and Power

 

		(a)	Each of Ampliphi and the Purchaser is a corporation duly organized,
                                         validly existing and in good standing under the laws of its jurisdiction of organization.

 

		(b)	Each of Ampliphi and the Purchaser has
                                         the corporate power to own its properties and to carry on its business as now being conducted
                                         and as proposed to be conducted and is duly qualified to do business and is in good standing
                                         in each jurisdiction in which the failure to be so qualified and in good standing would
                                         cause a have a material adverse effect on Ampliphi’s Group, taken as a whole.

 

		(c)	Ampliphi and the Purchaser have Disclosed a true and correct
                                         copy of the Articles or Certificate of Incorporation and Bylaws or other charter documents,
                                         as applicable (the “Purchaser Charter Documents”), of Ampliphi and
                                         Purchaser, each as amended to date.

 

		2.	Capital Structure

 

		(a)	The authorized capital stock of Ampliphi consists of 445,000,000
                                         shares of common stock, $0.01 par value (Common Stock), of which 44,923,045 shares were
                                         issued and outstanding as of the close of business on Monday 27 August 2012, and 10,000,000
                                         shares of preferred stock, $0.01 par value, 180,000 of which have been designated Series
                                         A preferred stock, none of which were issued and outstanding as of the close of business
                                         on Monday 27 August 2012, 7,034,782 warrants with an exercise price of $1.50 which expire
                                         in June 2013 and 1,693,956 warrants with an exercise price of $0.46 which expire in December
                                         2016 and 3,686,000 convertible loan notes which are due and convertible at Ampliphi’s
                                         discretion in June 2013 priced at $0.20 per share or the market price of Ampliphi Shares
                                         at the time of conversion if this is lower than $0.20.

 

		(b)	The authorized capital stock of the
                                         Purchaser consists of 10 ordinary shares and 100% of the issued and outstanding shares
                                         in the Purchaser are owned by Ampliphi.

 

		(c)	As of the close of business on 28 August 2012, Ampliphi has reserved
                                         4,200,000 shares of Common Stock for issuance to employees, directors and independent
                                         contractors pursuant to Ampliphi’s Stock Option Plan (as defined below), of which
                                         0 shares have been issued pursuant to option exercises, and 4,200,000 shares are subject
                                         to outstanding, unexercised options.

 

		(d)	There are no other outstanding shares of capital stock or voting
                                         securities of Ampliphi other than shares of Common Stock issued after 28 August 2012
                                         upon the exercise of options issued under Ampliphi’s Stock incentive Plan (the
                                         “Ampliphi Stock Option Plan”).

 

		(e)	Other than as contemplated under this Deed, except as Disclosed
                                         there are no other subscriptions, options, warrants, calls, rights, commitments or agreements
                                         of any character to which Ampliphi is a party or by which Ampliphi or the Purchaser is
                                         bound obligating Ampliphi or Purchaser to issue, deliver, sell, repurchase or redeem,
                                         or cause to be issued, delivered, sold, repurchased or redeemed, any shares of the capital
                                         stock of Ampliphi or Purchaser, or obligating Ampliphi or Purchaser to grant, extend
                                         or enter into any such subscription, option, warrant, call, right, commitment or agreement.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 37

    	 	Shareholder Sale Agreement

    

 

		(f)	The Consideration Shares to be issued
                                         by Ampliphi pursuant to this agreement will each be duly authorized, validly issued,
                                         fully paid, and non-assessable.

 

		3.	Authority

 

		(a)	Ampliphi and Purchaser each have all requisite corporate power
                                         and authority to enter into this agreement and to consummate the transactions contemplated
                                         hereby.

 

		(b)	The making of the Offer and the execution
                                         and delivery of this agreement, and the consummation of the transactions contemplated
                                         by this agreement have been duly authorized by all necessary corporate action on the
                                         part of Ampliphi and Purchaser, and no other corporate proceedings on the part of Ampliphi
                                         or Purchaser are necessary to authorize the Offer or this agreement, as applicable, or
                                         to consummate the transactions contemplated by this agreement.

 

		(c)	This agreement has been duly executed and delivered by Ampliphi
                                         and Purchaser and constitutes the valid and binding obligations of Ampliphi and Purchaser,
                                         and is enforceable in accordance with its terms, except as such enforcement may be limited
                                         by general equitable principles, or by bankruptcy, insolvency and other similar laws
                                         affecting the enforcement of creditors rights generally.

 

		4.	No Conflict; Required Filings and
                                         Consents

 

		(a)	The execution and delivery of this agreement does not, and the
                                         consummation of the transactions contemplated hereby will not:

 

		(i)	contravene, conflict with, or violate
                                         any provision of any constitution, statute, regulation, rule, injunction, judgment, order,
                                         decree, ruling, charge or other restriction of any Government Agency, court, administrative
                                         panel or other tribunal to which Ampliphi or Purchaser is subject,

 

		(ii)	conflict with, result in a breach of,
                                         constitute a default (or an event or condition which, with notice or lapse of time or
                                         both, would constitute a default) under, result in the acceleration of, create in any
                                         party the right to accelerate, terminate, modify or cancel, or require any notice under
                                         any agreement, contract, material mortgage, indenture, lease, license, instrument, permit,
                                         concession, franchise or other arrangement to which Ampliphi or the Purchaser is a party
                                         or by which it is bound, or to which any member of Ampliphi’s Group’s assets
                                         or properties are subject; or

 

		(iii)	result in or require the creation
                                         or imposition of any Encumbrance of any nature upon or with respect to any of any member
                                         of Ampliphi Group’s assets, including without limitation any shares of capital
                                         stock of Ampliphi or Purchaser.

 

		(b)	No consent, approval, order or authorization of, or registration,
                                         declaration or filing with, any Government Agency, is required by or with respect to
                                         Ampliphi or Purchaser in connection with the execution and delivery of the Offer or this
                                         agreement by Ampliphi or Purchaser or the consummation by Ampliphi or Purchaser of the
                                         transactions contemplated hereby except for:

 

		(i)	any filings as may be required under U.S. federal securities
                                         laws and any applicable state securities laws; and

 

		(ii)	such other consents, authorizations, filings, approvals and
                                         registrations which, if not obtained or made, would not have a material adverse effect
                                         on Ampliphi or Purchaser and would not prevent, materially alter or delay any the transactions
                                         contemplated by this agreement.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 38

    	 	Shareholder Sale Agreement

    

 

		5.	Financial Statements

 

The
audited consolidated financial statements of Ampliphi for the years ended 31 December 2009, and 31 December 2010, and the
final management accounts (in process of audit) for the year ended 31 December 2011 and unaudited financial statements for the
six month period ended 30 June 2012 (collectively, the “Accounts”), have been prepared in accordance
with U.S. GAAP applied on a basis consistent throughout the periods indicated consistent with each other (except as may be indicated
in the notes to those accounts and they may not contain all footnotes required by U.S. GAAP). The Accounts fairly present the
consolidated financial condition and operating results of Ampliphi and its subsidiaries at the dates and during the periods indicated
in those Accounts (subject, in the case of unaudited statements, to normal, recurring year-end adjustments). There has been no
change in Ampliphi accounting policies except as described in the notes to the Accounts.

 

		6.	Disclosure of material matters

 

		(a)	Ampliphi and the Purchaser have provided the Company or representatives
                                         of the Company with all material information known to them at the time that would be
                                         reasonably required by directors of the Company for deciding whether to recommend the
                                         transaction to the Vendors. With respect to any projections or future operations that
                                         may have been included in materials disclosed by Ampliphi or the Company in connection
                                         with the transactions contemplated by this Agreement, and any related transaction documents,
                                         Ampliphi and the Purchaser make no warranties.

 

		(c)	Neither Ampliphi nor the Purchaser have any material obligations
                                         or liabilities of any nature (mature or unmatured, fixed or contingent) except for those:

 

		(i)	disclosed in the Accounts;

 

		(ii)	Disclosed; or

 

		(iii)	incurred in the ordinary course
                                         of business.

 

		(d)	From February 2012 until the Execution Date, Ampliphi has
                                         conducted its business in the ordinary course in a manner consistent with past practice
                                         and, except for the sale of Ampliphi’s assets relating to the former business of
                                         Targeted Genetics Corporation, there has not been any change, event or condition that
                                         has resulted, or is likely to result, in a Purchaser Material Adverse Change.

 

		(e)	Ampliphi and the Purchaser intend to take commercially reasonable
                                         steps to fund the combined business of Ampliphi and the Company following the Completion
                                         Date.

 

		7.	Litigation

 

There
is no:

 

		(i)	private or governmental action, suit, proceeding, claim, arbitration
                                         or investigation pending before any agency, court or tribunal, foreign or domestic, or,
                                         to the knowledge of Ampliphi, threatened against any member of Ampliphi’s Group
                                         or any of their respective properties or any of their respective officers or directors
                                         (in their capacities as such); or

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 39

    	 	Shareholder Sale Agreement

    

 

		(ii)	judgment, decree or order against any member of Ampliphi’s
                                         Group or, to the knowledge of Ampliphi or Purchaser, or any of their respective directors
                                         or officers (in their capacities as such), that could, in each of (i) and (ii), prevent,
                                         enjoin, or materially alter or delay any of the transactions contemplated by this agreement
                                         or that could reasonably be expected to cause a Purchaser Material Adverse Change.

 

		8.	Compliance with Laws

 

To
the knowledge of Ampliphi and the Purchaser each member of Ampliphi’s Group complies with all applicable laws, permits and
authorisations and will applicable industry codes of conduct, in relation to the continuing operation of their business and the
ownership and use of their assets, where non-compliance would, if unremedied, result in a liability or a restriction which would
materially and adversely affect the business as currently carried on by the relevant member of Ampliphi’s Group.

 

		9.	Title to and Condition of Properties

 

Each
member of Ampliphi’s Group owns or holds, under valid leases or other rights to use, all real property, plants, machinery
and equipment necessary for the conduct of their respective businesses as presently conducted, except where the failure to own
or hold such property, plants, machinery and equipment would not cause a Purchaser Material Adverse Change. The material buildings,
plants, machinery and equipment necessary for the conduct of each member of the Ampliphi’s Group’s respective businesses
as presently conducted are structurally sound, are in good operating condition and repair and are adequate for the uses to which
they are being put, in each case, taken as a whole, and none of such buildings, plants, machinery or equipment are in need of
maintenance or repairs, except for ordinary, routine maintenance and repairs that are not material in nature or cost.

 

		10.	Intellectual Property Rights

 

		(a)	Ampliphi’s Group owns, free and clear from all Encumbrances,
                                         all Intellectual Property Rights which were owned by Biocontrol Limited (a UK company)
                                         at the time of its acquisition by Ampliphi (or a subsidiary of Ampliphi).

 

		(b)	No member of Ampliphi’s Group has received any communications
                                         alleging that any member of Ampliphi’s Group has violated or, by conducting their
                                         respective businesses as conducted, violates the Intellectual Property Rights of any
                                         other person or entity, and to Ampliphi’s knowledge, the business as conducted
                                         will not cause any member of Ampliphi’s Group to infringe or violate the Intellectual
                                         Property Rights of any other person or entity.

 

		11.	Tax Matters

 

		(a)	All tax returns required to be filed by or on behalf of Ampliphi
                                         with any Government Agency before the Completion Date:

 

		(i)	have been or will be filed on or before
                                         the applicable due date (including any extensions of such due date); and

 

		(ii)	have been, or will be when filed, accurately
                                         and completely prepared in all material respects in compliance with all applicable requirements
                                         of the applicable taxing jurisdictions.

 

		(b)	All Taxes owed by Ampliphi have been paid when due, whether or
                                         not such amounts are shown on any tax returns. The Ampliphi Accounts fully accrue all
                                         actual and contingent liabilities for unpaid Taxes with respect to all periods through
                                         the date of those Accounts and Ampliphi has made adequate provision for unpaid Taxes
                                         after that date in its books and records.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 40

    	 	Shareholder Sale Agreement

    

 

		(c)	No tax return has been examined or audited by any Government
                                         Agency. No claim or legal proceeding is pending or, to the knowledge of Ampliphi, has
                                         been threatened against or with respect to Ampliphi in respect of any Tax. There are
                                         no unsatisfied liabilities for Taxes, including liabilities for interest, additions to
                                         tax and penalties thereon and related expenses, with respect to which any notice of deficiency
                                         or similar document has been received by Ampliphi (other than liabilities for Taxes asserted
                                         under any such notice of deficiency or similar document which are being contested in
                                         good faith by Ampliphi and with respect to which adequate reserves for payment have been
                                         established). There are no liens for Taxes upon any of the assets of Ampliphi except
                                         liens for current Taxes not yet due and payable.

 

		12	Insurance

 

		(a)	Each material insurance policy (including fire, theft, casualty,
                                         general liability, director and officer, workers compensation, business interruption,
                                         environmental, product liability and automobile insurance policies and bond and surety
                                         arrangements) to which any member of Ampliphi’s Group is a party, a named insured,
                                         or otherwise the beneficiary of coverage at any time within the past year has been Disclosed.
                                         Each such insurance policy is in full force and effect and by its terms and with the
                                         payment of the requisite premiums thereon will continue to be in full force and effect
                                         following the Completion Date.

 

		(b)	No member of Ampliphi’s Group is in breach or default,
                                         and does not anticipate being in breach or default after the Completion Date (including
                                         with respect to the payment of premiums or the giving of notices) under any such insurance
                                         policy, and no event has occurred which, with notice or the lapse of time, would constitute
                                         such a breach or default or permit termination, modification or acceleration, under such
                                         insurance policy; except for any breach, default, event, termination, modification or
                                         acceleration that would not cause a Purchaser Material Adverse Change; and neither Ampliphi
                                         nor any other member of Ampliphi’s Group has received any written notice or oral
                                         notice, from the insurer disclaiming coverage or reserving rights with respect to a particular
                                         claim or such policy in general. Ampliphi has not incurred any material loss, damage,
                                         expense or liability covered by any such policy for which it has not properly asserted
                                         a claim under such policy. Ampliphi and each other member of Ampliphi’s Group is
                                         fully insured to cover any existing claims for damages against any member of Ampliphi’s
                                         Group.

 

13.    
Exempt Issuance

 

Assuming
that all of the holders of the shares in the capital of Ampliphi either:

 

		(i)	are “accredited investors,” as such term is defined
                                         in Regulation D, and have complied with all of the terms and conditions of the Offer
                                         and this agreement, or

 

		(ii)	are not “U.S. Persons,” as such term is defined
                                         in Regulation S, have satisfied all of the requirements of Regulation S, and have complied
                                         with all of the terms and conditions of the Offer and this agreement,

 

then
the offer and sale of shares by Purchaser and Ampliphi, respectively, under the Offer and this agreement will be exempt from the
registration requirements of the Securities Act and in compliance with all U.S. federal and state securities law.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 41

    	 	Shareholder Sale Agreement

    

 

PART
B: Limitations

 

		1.	Time Limits

 

Ampliphi
and the Purchaser shall not be liable for any Purchaser Claim unless the Vendor Representative gives written notice of the Purchaser
Claim to Ampliphi and the Purchaser (containing reasonable details of the nature of the Purchaser Claim), within 12 months of
the Completion Date. This time limit will not apply to any Purchaser Claim relating to a breach of any of the warranties relating
to Tax matters in Schedule 3, Part A paragraph 11.

 

		2.	Withdrawal

 

Any
Purchaser Claim shall (if it has not been previously satisfied, settled or withdrawn) be deemed to have been withdrawn unless
legal proceedings in respect of it have been commenced by both being issued and served within 6 months after notice has been given
by the Vendor Representative in accordance with Paragraph 1 of this Part B of Schedule 3, except where the Purchaser Claim relates
to a contingent liability in which case it shall be deemed to have been withdrawn unless legal proceedings in respect of it have
been commenced by being both issued and served within 6 months of it having become an actual liability.

 

		3.	Maximum Liability
                                         and Thresholds

 

		(a)	Except in the case of fraud or evasion, the maximum aggregate
                                         liability of Ampliphi and the Purchaser for all Purchaser Claims shall not exceed an
                                         amount equal to the cash equivalent of the Market Value of the total Contingent Shares
                                         and Escrow Shares attributable to the Management Vendors, calculated as at Completion.

 

		(b)	The Purchaser and Ampliphi shall not be liable for any single
                                         Purchaser Claim unless the amount of the liability pursuant to that single Purchaser
                                         Claim exceeds US$50,000; for these purposes, individual Purchaser Claims arising from
                                         the same, substantially the same or similar or related facts or circumstances shall be
                                         aggregated to form one and the same Purchaser Claim.

 

		4.	Acts or Omissions
                                         of the Purchaser

 

Ampliphi
and the Purchaser shall not be liable for any Purchaser Claim which would not have arisen but for any voluntary act, omission
or transaction carried out:

 

		(a)	after the date of
                                         this agreement by any Vendor; or

 

		(b)	before Completion by any member of Ampliphi’s Group at
                                         the written direction or request of any Vendor or any affiliate of such Vendor,

 

and
which, in any such case, the Vendor or affiliate was actually aware or ought reasonably to have been aware that such act, omission
or transaction would give or is likely to give rise to the Purchaser Claim in question.

 

		5.	Duty to Mitigate

 

Nothing
in this Part B of Schedule 3 shall restrict or limit the general obligation at law of any Vendor to mitigate any Loss which it
may suffer in consequence of any breach by Ampliphi or the Purchaser of any of the Purchaser Warranties.

 

		6.	Conduct of Claims

 

If
the Vendor Representative becomes aware of any claim by a third party which might reasonably be expected to result in a Purchaser
Claim being made (a “Third Party Claim”) the Vendor Representative shall:

 

		(a)	within 20 Business Days of becoming aware of it, give written
                                         notice of such Third Party Claim to Ampliphi and the Purchaser containing such details
                                         of the Third Party Claim as the Vendor Representative has available to it, but so that
                                         any failure by the Vendor Representative to give such notice within such period shall
                                         not prejudice the right of any Vendor to make a Claim in relation to such Third Party
                                         Claim;

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 42

    	 	Shareholder Sale Agreement

    

 

		(b)	not make (and procure that no Vendor shall make) any admission
                                         of liability, agreement or compromise to or with any person in relation to that Third
                                         Party Claim without the prior written consent of Ampliphi and the Purchaser (such consent
                                         not to be unreasonably withheld or delayed); and

 

		(c)	subject to the Vendor Representative being indemnified to its
                                         reasonable satisfaction by Ampliphi and/or the Purchaser against all Loss incurred in
                                         respect of that Third Party Claim take (and procure that each Vendor shall take) such
                                         action as the Purchaser and Ampliphi may reasonably request to avoid, resist, dispute,
                                         appeal, compromise or defend such Third Party Claim.

 

		7.	Recovery From Third
                                         Parties

 

If
Ampliphi and/or the Purchaser makes any payment to any Vendor in relation to a Purchaser Claim (the “Damages Payment”)
and the Vendor receives any sum or benefit otherwise than from Ampliphi and/or the Purchaser (whether by payment, discount,
credit, relief or otherwise, and including from any Tax authority) which would not have been received but for the circumstances
giving rise to that Purchaser Claim, the Vendor Representative shall procure that that Vendor shall (once the relevant Vendor
has received such sum or benefit) immediately repay to Ampliphi and/or the Purchaser an amount equal to such sum or benefit (net
of taxation on that amount and reasonable costs of recovery) or, if less, the Damages Payment.

 

		8.	Changes in Law, Tax
                                         Rates and Accounting Policies

 

Ampliphi
and/or the Purchaser shall not be liable for any Purchaser Claim if and to the extent that it is attributable to or the amount
of such Purchaser Claim is increased as a result of:

 

		(a)	any legislation not
                                         in force at the date of this agreement;

 

		(b)	any change of law, regulation, directive, requirement or administration
                                         practice which takes effect retroactively; or

 

		(c)	any change in the
                                         rates of tax in force at the date of this agreement.

 

		9.	No Double Recovery

 

No
Vendor shall be entitled to recover damages or obtain payment, reimbursement, restitution or indemnity more than once in respect
of any one liability, loss or breach or other set of circumstances which give rise to more than one Purchaser Claim.

 

		10.	General

 

		(a)	Ampliphi and the Purchaser shall not be liable for a Purchaser
                                         Claim if and to the extent that the fact, matter, event or circumstance giving rise to
                                         such Purchaser Claim was Disclosed in the Purchaser Disclosure Letter.

 

		(b)	Ampliphi and the Purchaser shall not be liable in respect of
                                         any Purchaser Claim where the liability which is the subject matter of such Purchaser
                                         Claim is contingent only, unless and until such contingent liability becomes an actual
                                         liability and is due and payable.

 

DEFINITIONS

 

In
this Schedule 3, unless the context requires otherwise

 

“Ampliphi’s
Group” means Ampliphi, Biocontrol Limited and any subsidiary of Ampliphi.

 

“Disclosed”
means fairly disclosed to the Company, the Vendor Representative or the Vendors with sufficient detail to allow the recipient
to make an informed assessment of the nature and scope of the matters, facts and circumstances disclosed.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 43

    	 	Shareholder Sale Agreement

    

 

“Purchaser
Claim” means any claim for breach of the Purchaser Warranties.

 

“Purchaser
Disclosure Letter” means any disclosure letter dated on or about the date of this agreement from Ampliphi and the Purchaser
to the Vendor Representative.

 

“SEC”
means the U.S. Securities Exchange Commission.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 44

    	 	Shareholder Sale Agreement

    

 

Schedule
4     Contingent Shares

 

		1.	Conditions

 

Upon
each condition within paragraphs 1(a), (b) or (c) (“Contingent Payment Conditions”) being satisfied, the Purchaser
will cause the Escrow Agent to allocate to the Managers, in accordance with paragraph 5 below, one third of the Contingent Shares
attributable to each of the Managers (subject to any claims made on those Contingent Shares):

 

		(a)	the first dose is administered in a
                                         human clinical trial using phage therapy involving a phage mix that has been discovered,
                                         developed and produced by the Company’s legacy technology;

 

		(b)	the Group completes a treatment trial in the United States and/or
                                         United Kingdom of infection in horses utilizing phage therapy involving a phage mix that
                                         has been discovered, developed and produced by the Company’s legacy technology
                                         and where such trial includes the completion of=treatment of at least 12 horses
                                         from 30 June 2012; and

 

		(c)	the Group completes the production at the Company’s production
                                         facility of at least 10 litres of an Ampliphi or Company or combined Ampliphi and Company
                                         phage therapy mix suitable for use in pre-clinical and clinical trials.

 

For
the purposes of this Schedule 4, “Group” means the Company, the Purchaser and/or Ampliphi.

 

		2.	Best endeavours

 

The
Purchaser must use, and must ensure that the Group uses, their best endeavours to satisfy the Contingent Payment Conditions within
24 months of the Completion Date (“Contingent End Date”). If any Contingent Payment Condition
is not met as a result of:

 

		(a)	the Group’s failure to use best
                                         endeavours to achieve that condition; or

 

		(b)	a force majeure event (being a natural
                                         and unavoidable catastrophe that interrupts the expected course of events),

 

then
the Contingent Payment Condition will be deemed to have been satisfied on the Contingent End Date.

 

		3.	Information and Notice

 

		(a)	The Purchaser must provide the Managers with full access to all
                                         information relating to the Group’s progress on the Contingent Payment Conditions
                                         and the steps that are being taken by the Group to satisfy the Contingent Payment Conditions.

 

		(b)	The Purchaser must promptly notify the
                                         Managers in writing if it becomes aware that a Contingent Payment Condition has been
                                         satisfied.

 

		(c)	At any time prior to the Contingent
                                         End Date, the Managers may notify the Purchaser in writing if the Managers believe that
                                         a Contingent Payment Condition has been satisfied. The Purchaser must either accept or
                                         reject the Manager’s notice within 20 Business Days of receiving the notice. If
                                         a notice is rejected, or the Purchaser does not respond within 20 Business Days of receiving
                                         a notice, then a dispute (“Contingent Payment Dispute”) will be deemed
                                         to have arisen and such dispute will be dealt with in accordance with paragraph 4 of
                                         this Schedule 4.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 45

    	 	Shareholder Sale Agreement

    

 

		(d)	If the Purchaser believes that any of
                                         the Contingent Payment Conditions have not been satisfied by the Contingent End Date,
                                         then the Purchaser must notify the Managers in writing of the non-satisfaction of the
                                         Contingent Payment Condition. If the Managers wish to dispute the Purchaser’s notice,
                                         then the Managers must deliver a written notice to the Purchaser notifying it as such
                                         within 20 Business Days of receipt of the Purchaser’s notice and the dispute must
                                         be dealt with in accordance with paragraph 4 of this Schedule 4.

 

		4.	Dispute

 

		(a)	The Managers and the Purchaser must enter into good faith
                                         negotiations and use all reasonable endeavours to resolve any Contingent Payment Dispute.

 

		(b)	If the Managers and the Purchaser do not resolve the Contingent
                                         Payment Dispute within 20 Business Days after written notice of the Contingent Payment
                                         Dispute is given (or such longer period as the Purchaser and the Managers agree) then
                                         the Contingent Payment Dispute must be referred for resolution to an independent expert
                                         agreed by the Managers and the Purchaser within a further 5 Business Days. If they cannot
                                         agree on who the independent person will be within that time period, either of the Managers
                                         or the Purchaser may request the president, at that time, of the Institute of Arbitrators
                                         and Mediators Australia (or the president’s nominee) to appoint an independent
                                         expert to resolve the Contingent Payment Dispute. The person agreed or nominated under
                                         this clause (b) will be the ‘Expert’ for the purposes of this
                                         Schedule 4.

 

		(c)	The Purchaser and the Managers must instruct the Expert
                                         to decide within the shortest practicable time whether the Contingent Payment Condition
                                         has been satisfied, and to deliver to the Purchaser and the Managers a report (Expert’s
                                         Report) which states, on the basis of the Expert’s decision, its opinion
                                         as to whether the Contingent Payment Condition has been satisfied.

 

		(d)	The Expert will act as an expert,
                                         not as an arbitrator, in determining the dispute.

 

		(e)	The Expert’s determination in relation to whether
                                         the Contingent Payment Condition has been satisfied must be made as soon as possible.

 

		(f)	The Expert’s decision is final, conclusive and binding
                                         (except in the case of manifest error).

 

		(g)	The parties hereto will endeavour to procure that the engagement
                                         documents for the Expert will provide for such Expert to endeavour to provide a decision
                                         within 10 Business Days of appointment, subject to delays resulting from the action or
                                         inaction of the Purchaser or the Managers.

 

		(h)	Each party must bear its own costs
                                         in complying with this paragraph 4.

 

		(i)	The cost of the Expert (if appointed) must be shared equally
                                         and paid by the Vendors and the Purchaser.

 

		(j)	For the avoidance of doubt, all
                                         decision-making in respect of the Purchaser’s conduct of any Contingent Payment
                                         Dispute will be conducted by Ampliphi’s representatives on the board of directors
                                         of the Purchaser.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 46

    	 	Shareholder Sale Agreement

    

 

		5.	Release of Contingent Shares

 

		(a)	The Contingent Shares must be issued
                                         to, and held by, the Escrow Agent for the period of 12 months from the Completion Date
                                         (“Escrow Period”), except that at the end of the Escrow
                                         Period, the Escrow Agent shall continue to hold Contingent Shares with a value sufficient
                                         to satisfy any Claim for which any Manager may be liable under this agreement, or the
                                         Management Vendors’ Warranty Deed, for which the Purchaser or Ampliphi has provided
                                         notice and which has not been resolved as of the end of the Escrow Period (“Pending
                                         Claim”) until the final resolution of such Pending Claim.

 

		(b)	Following the Escrow Period the
                                         Purchaser must procure the Escrow Agent to:

 

		A.	if a Contingent Payment Condition has been satisfied during
                                         the Escrow Period, the Contingent Shares are not subject to a Claim under this agreement
                                         or under the Management Vendors’ Warranty Deed and there is no Contingent Payment
                                         Dispute release the relevant Contingent Shares to the Managers within 10 Business Days
                                         of the end of the Escrow Period;

 

		B.	if a Contingent Payment Condition is satisfied after the
                                         Escrow Period but before Contingent End Date, the Contingent Shares are not subject to
                                         a Claim under this agreement or under the Management Vendors’ Warranty Deed and
                                         there is no Contingent Payment Dispute release the relevant Contingent Shares to the
                                         Managers within 10 Business Days of the satisfaction of the Contingent Payment Condition;
                                         or

 

		C.	if the Contingent Shares are subject to a Claim under this
                                         agreement, under the Management Vendors’ Warranty Deed or in a Contingent Payment
                                         Dispute that is determined in favour of the Managers release the relevant Contingent
                                         Shares to the Managers within 10 Business Days of the Claim being finally determined.

 

		6.	Failure to meet conditions

 

If
the Contingent Payment Conditions are not met by the Contingent End Date the Purchaser may direct the Escrow Agent to deal with
the Contingent Shares in any way that it sees fit and the Managers shall have not claim to the Contingent Shares.

 

		7.	Escrow restrictions

 

While
the Escrow Agent holds the Contingent Shares, the Managers may not, and until the Contingent End Date the Purchaser must procure
that the Escrow Agent does not, do any of the following:

 

		(a)	dispose of, or
                                         agree or offer to dispose of, the Contingent Shares;

 

		(b)	create, or agree or offer to create, any security interest
                                         in the Contingent Shares; or

 

		(c)	do, or omit to do, any act if the act or omission would have
                                         the effect of transferring effective ownership or control of the Contingent Shares.

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 47

    	 	Shareholder Sale Agreement

    

 

	Execution Page	 	 	 
	 	 	 	 
	Executed as an agreement on	 	8th September 2012	

 

	SIGNED by Anthony Smithyman in the	 	)
	presence of:	 	)
	 	 	)
	 	 	 
	/s/  G-Halli Rajasekariah	 	/s/ Anthony Smithyman
	Signature of Witness	 	Signature of Anthony Smithyman
	 	 	 
	Dr G-Halli Rajasekariah	 	 
	Name of Witness	 	 
	(Please print)	 	 
	 	 	 
	SIGNED by Margaret Smithyman in the	 	)
	presence of: 	 	)
	 	 	)
	 	 	 
	/s/ James Algar	 	/s/ Margaret Smithyman
	Signature of Witness	 	Signature of Margaret Smithyman
	 	 	 
	Mr. James Algar	 	 
	Name of Witness	 	 
	(Please print)	 	 

 

	EXECUTED by AMPLIPHI AUSTRALIA PTY	 	 
	LTD in accordance with section 127(1) of the	 	 
	Corporations Act 2001	 	 
	 	 	 
	/s/ Philip Young	 	/s/ Andrew Walker
	Signature of Director	 	Signature of Director / Company Secretary
	 	 	(delete as applicable)
	 	 	 
	Philip Young	 	Andrew Walker
	Name of Director	 	Name of Director / Company Secretary
	(Please print)	 	(Please print)

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 48

    	 	Shareholder Sale Agreement

    

 

	EXECUTED by Ampliphi Biosciences	 	 
	Corporation	 	 
	 	 	 
	 	 	 
	Signature of Director	 	Signature of Director/ Company Secretary
	 	 	(delete as applicable)
	 	 	 
	 	 	 
	Name of Director	 	Name of Director/ Company Secretary
	(Please print)	 	(Please print)
	 	 	 
	SIGNED by Jean Crease atf Doug & Jean	 	)
	Crease Super Fund in the presence of:	 	)
	 	 	 
	/s/ Anthony Wragg	 	/s/ Jean Crease
	Signature of Witness	 	Signature of Jean Crease
	 	 	 
	Anthony Wragg	 	 
	Name of Witness	 	 
	(Please print)	 	 
	 	 	 
	SIGNED by Doug Crease atf Doug & Jean	 	)
	Crease Super Fund in the presence of:	 	)
	 	 	 
	/s/ Karan Stewart	 	/s/ Doug Crease
	Signature of Witness	 	Signature of Doug Crease
	 	 	 
	 	 	 
	Karan Stewart	 	 
	Name of Witness 	 	 
	(Please print)	 	 

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 49

    	 	Shareholder Sale Agreement

    

 

	EXECUTED by APG Nominees Pty Ltd as	)	 
	trustee for The AP Gellert Family Trust	)	 
	and in accordance with section 127 (1) of	)	 
	the Corporations Act 2001 	 	 
	 	 	 
	/s/ Anthony Gellert	 	/s/ Jennifer Gellert
	Signature of Director	 	Signature of Director
	 	 	(delete as applicable) 
	 	 	 
	Anthony Gellert	 	Jennifer Gellert
	Name of Director	 	Name of Director
	(Please print)	 	(Please print)
	 	 	 
	EXECUTED by APG Nominees Pty Ltd as	)	 
	trustee for The AP Gellert Superannuation	)	 
	Fund and in accordance with section 127(1) of	)	 
	the Corporations Act 2001	 	 
	 	 	 
	/s/ Anthony Gellert	 	/s/ Jennifer Gellert
	Signature of Director	 	Signature of Director 
	 	 	(delete as applicable)
	 	 	 
	Anthony Gellert	 	Jennifer Gellert
	Name of Director	 	Name of Director 
	(Please print)	 	(Please print)
	 	 	 
	EXECUTED by Camdare Pty Ltd in	)	 
	accordance with section 127(1) of the	)	 
	Corporations Act 2001	)	 
	 	 	 
	 	 	/s/ Julie Thompson
	Signature of Director	 	Signature of Director  / Sole Director
	 	 	(delete as applicable)
	 	 	 
	 	 	Julie Joy Thompson
	Name of Director	 	Name of Director
	(Please print)	 	(Please print)

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 50

    	 	Shareholder Sale Agreement

    

 

	EXECUTED by Gabodi Pty Ltd in accordance	)	 
	with section 127(1) of the Corporations Act	)	 
	2001	)	 
	 	 	 
	/s/ Angela Flannery	 	/s/ [ILLEGIBLE]
	Signature of Director	 	Signature of Director / Company Secretary
	 	 	(delete as applicable)
	 	 	 
	Angela Flannery	 	[ILLEGIBLE]
	Name of Director	 	Name of Director / Company Secretary
	(Please print)	 	(Please print)
	 	 	 
	EXECUTED by Maxivend Pty Ltd as trustee	)	 
	for David Hale Super Fund and in accordance	)	 
	with section 127(1) of the Corporations Act	)	 
	2001	 	 
	 	 	 
	/s/ David Gordon Hale	 	/s/ Lisa Jane Hale
	Signature of Director	 	Signature of Director 
	 	 	(delete as applicable)
	 	 	 
	David Gordon Hale	 	Lisa Jane Hale
	Name of Director	 	Name of Director
	(Please print)	 	(Please print)
	 	 	 
	EXECUTED by Biofirm Pty Ltd in accordance	)	 
	with section 127(1) of the Corporations Act	)	 
	2001	)	 
	 	 	 
	/s/  G-Halli Rajasekariah	 	/s/  Poornima Rajasekariah
	Signature of Director	 	Signature of Director / Company Secretary
	 	 	(delete as applicable) 
	 	 	 
	Dr G-Halli Rajasekariah	 	Dr Poornima Rajasekariah
	Name of Director	 	Name of Director / Company Secretary
	(Please print) 	 	(Please print)

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 51

    	 	Shareholder Sale Agreement

    

 

	EXECUTED by Arapahoe Pty Ltd in	)	 
	accordance with section 127(1) of the	)	 
	Corporations Act 2001	)	 
	 	 	 
	/s/ Neil Pickup	 	 
	Signature of Director	 	Signature of Director / Company Secretary
	 	 	(delete as applicable)
	 	 	 
	Neil Pickup	 	 
	Name of Director	 	Name of Director / Company Secretary
	(Please print)	 	(Please print)
	 	 	 
	 	 	 
	EXECUTED by Shigetsugu Pty Ltd as trustee	)	 
	for G Symes Superfund and in accordance	)	 
	with section 127(1) of the Corporations Act	)	 
	2001	 	 
	 	 	 
	/s/ Grant R. Symes	 	 
	Signature of Director	 	Signature of Director / Company Secretary
	 	 	(delete as applicable)
	 	 	 
	Grant R. Symes	 	 
	Name of Director	 	Name of Director / Company Secretary
	(Please print)	 	(Please print) 
	 	 	 
	EXECUTED by Jalba Pty Ltd in accordance	)	 
	with section 127(1) of the Corporations Act	)	 
	2001	)	 
	 	 	 
	/s/ Andrew Sneddon	 	/s/ Judith Sneddon
	Signature of Director	 	Signature of Director / Company Secretary
	 	 	(delete as applicable)
	 	 	 
	Andrew Sneddon	 	Judith Sneddon
	Name of Director	 	Name of Director / Company Secretary
	(Please print) 	 	(Please print)
	 	 	 
	SIGNED by Warren J Dick in the presence of:	)	 
	 	)	 
	 	 	 
	/s/ David Ireland	 	/s/ Warren J Dick
	Signature of Witness	 	Signature of Warren J Dick
	 	 	 
	David Ireland	 	 
	Name of Witness	 	 
	(Please print) 	 	 

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 52

    	 	Shareholder Sale Agreement

    

 

	SIGNED by
    Pierre Issa Saliba in the presence	)	 	 
	of:	)	 	 
	 	 	 	 
	/s/ Begard Marof	 	 	/s/ Pierre Issa Saliba
	Signature of Witness	 	 	Signature of Pierre Issa Saliba
	 	 	 	
	Begard Marof	 	 	 
	Name of Witness	 	 	 
	(Please print)	 	 	 
		 	 	 
	EXECUTED by TCS Biosciences
    Ltd in	)	 	 
	accordance with section 127(1)
    of the	)	 	 
	Corporations Act 2001	)	 	 
	 	 	 	 
	/s/ Lynda Preston	 	 	 
	Signature of Director	 	 	Signature of Director / Company Secretary
	 	 	 	(delete as applicable)
	 	 	 	 
	Lynda Prestion	 	 	 
	Name of Director	 	 	Name of Director / Company Secretary
	(Please print)	 	 	(Please print)
	 	 	 	 
	SIGNED by Alastair
    Winter in the presence of:	)	 	 
	 	)	 	 
	/s/ Michael Barker	 	 	/s/ Alastair Winter
	Signature of Witness	 	 	Signature of Alastair Winter
	 	 	 	
	Michael Barker	 	 	 
	Name of Witness	 	 	 
	(Please print)	 	 	 
	 	 	 	 
	EXECUTED by Argyle Europe
    Limited in	)	 	 
	accordance with section 127(1)
    of the	)	 	 
	Corporations Act 2001	)	 	 
	 	 	 	 
	 	 	 	/s/ A.C. Hibbert
	/s/ Alastair Winter	 	 	Signature of Director
	Signature of Director	 	 	(delete as applicable)
	 	 	 	
	Alastair Winter	 	 	A.C. Hibbert
	Name of Director	 	 	Name of Director
	(Please print)	 	 	(Please print)

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 53

    	 	Shareholder Sale Agreement

    

 

	SIGNED by Anita Hibbert in the presence
    of:	)	 	 
	 	)	 	 
	 		 	 
	 	 	 	 
	/s/ Samantha Benge	 	 	/s/ Anita Hibbert
	Signature of Witness	 	 	Signature of Anita Hibbert
	 	 	 	
	Samantha Benge	 	 	 
	Name of Witness 	 	 	 
	(Please print) )	 	 	 
	 	 	 	 
	SIGNED by Howard Wigham
    in the presence 	)	 	 
	of:	)	 	 
	 	 	 	 
	/s/ Jamie Kelsall	 	 	/s/ Howard Wigham
	Signature of Witness	 	 	Signature of Howard Wigham
	 	 	 	
	Jamie Kelsall	 	 	 
	Name of Witness 	 	 	 
	 (Please print)	 	 	 
	 	 	 	 
	EXECUTED by Girby Corporation
    Pty Ltd as	)	 	 
	trustee for Wigham Family Trust
    and in	)	 	 
	accordance with section 127(1)
    of the	)	 	 
	Corporations Act 2001	 	 	 
	 	 	 	 
	/s/ Steve Sherwood	 	 	/s/ Madelaine Wigham
	Signature of Director	 	 	Signature of Director
	 	 	 	(delete as applicable)
	 	 	 	 
	Steve Sherwood	 	 	Madelaine Wigham
	Name of Director 	 	 	Name of Director
	(Please print)	 	 	(Please print)
	 	 	 	 
	SIGNED by Hugh Hurst
    in the presence of:	)	 	 
	 	)	 	 
	 	 	 	 
	/s/ Alastair Winter	 	 	/s/ Hugh Hurst
	Signature of Witness	 	 	Signature of Hugh Hurst
	 	 	 	
	Alastair Winter

	 	 	 
	Name of Witness 	 	 	 
	(Please print)	 	 	 

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 54

    	 	Shareholder Sale Agreement

    

 

	SIGNED by Colleen
    Black in the presence of:	)	 	 
	 	)	 	 
	 	 	 	 
	/s/ Joanne Black	 	 	/s/ Colleen Black
	Signature of Witness	 	 	Signature of Colleen Black
	 	 	 	
	Joanne Black	 	 	 
	Name of Witness 	 	 	 
	(Please print)	 	 	 
	 	 	 	 
	SIGNED by Andrew Hibbert
    in the presence	)	 	 
	of:	)	 	 
	 	 	 	 
	/s/ Barre Juliette	 	 	/s/ Andrew Hibbert
	Signature of Witness	 	 	Signature of Andrew Hibbert
	 	 	 	
	Barre Juliette	 	 	 
	Name of Witness 	 	 	 
	(Please print)	 	 	 
	 	 	 	 
	SIGNED by Craig Lawn
    in the presence of:	)	 	 
	 	)	 	 
	 	 	 	 
	/s/ Joy Lawn	 	 	/s/ Craig Lawn
	Signature of Witness	 	 	Signature of Craig Lawn
	 	 	 	 
	Joy Lawn	 	 	
	Name of Witness	 	 	 
	(Please print)	 	 	 
	 	 	 	 
	SIGNED by Col. Samuel
    Martin in the	)	 	 
	presence of:	)	 	 
	 	 	 	 
	/s/ Sudhir Khetarpal	 	 	/s/ Col. Samuel Martin
	Signature of Witness	 	 	Signature of Col. Samuel Martin
		 	 	
	Sudhir Khetarpal	 	 	 
	Name of Witness 	 	 	 
	(Please print)	 	 	 

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 55

    	 	Shareholder Sale Agreement

    

 

	SIGNED by Wayne Hughes in the
    presence of:	)	 	 
	 	)	 	 
	 	 	 	 
	/s/ B. McConnell	 	 	/s/ Wayne Hughes
	Signature of Witness	 	 	Signature of Wayne Hughes
	 	 	 	 
	B. McConnell	 	 	
	Name of Witness	 	 	 
	(Please print)	 	 	 
	 	 	 	 
	SIGNED by Giles Hamilton
    in the presence of:	)	 	 
	 	)	 	 
	 	 	 	 
	/s/ Caren Morrison	 	 	/s/ Giles Hamilton
	Signature of Witness	 	 	Signature of Giles Hamilton
	 	 	 	 
	Caren Morrison	 	 	
	Name of Witness	 	 	 
	(Please print)	 	 	 
	 	 	 	 
	SIGNED by Peter Downes in the presence of:	)	 	 
	 	)	 	 
	/s/ Andrea Pulati	 	 	/s/ Peter Downes 
	Signature of Witness	 	 	Signature of Peter Downes
	 	 	 	 
	Andrea Pulati	 	 
	Name of Witness	 	 	 
	(Please print)	 	 	 
	 	 	 	 
	SIGNED by John Batty
    in the presence of:	)	 	 
	 	)	 	 
	 	 	 	 
	/s/
                                        Alastair Winter

		 	/s/ John Batty
	Signature of Witness	 	 	Signature of John Batty
	 	 	 	 
	Alastair Winter	 	 	
	Name of Witness	 	 	 
	(Please print)	 	 	 

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 56

    	 	Shareholder Sale Agreement

    

 

	EXECUTED by Glowcave
    Pty Ltd as trustee	)	 	 
	for Wood Super Fund and
    in accordance with	)	 	 
	section 127(1)
    of the Corporations Act 2001	)	 	 
	 	 	 	 
	/s/ Lynda
    Wood	 	 	/s/ Craig Wood
	Signature of	 	 	Signature of Director Company
    Secretary
	 	 	 	(delete as applicable)
	 	 	 	 
	Lynda Wood	 	 	Craig Wood
	Name of Director	 	 	Name of Director / Company Secretary
	(Please print)	 	 	(Please print)
	 	 	 	 
	EXECUTED by Wheeler Superannuation
    Pty	)	 	 
	Ltd in accordance with
    section 127(1) of the	)	 	 
	Corporations Act 2001	)	 	 
	 	 	 	 
	/s/ Colin John Cair	 	 	/s/ Kee Song Tan
	Signature of Director	 	 	Signature of Director / Company
    Secretary
	 	 	 	(delete as applicable)
	 	 	 	 
	Colin John Cair	 	 	Kee Song Tan
	Name of Director	 	 	Name of Director / Company Secretary
	(Please print)	 	 	(Please print)
	 	 	 	 
	SIGNED by Mervyn Hylton
    Chappel atf M & A	)	 	 
	Chappel Superfund in the
    presence of:	)	 	 
	 	 	 	 
	/s/ James Benson	 	 	/s/ Mervyn Hylton Chappel
	Signature of Witness	 	 	Signature of Mervyn Hylton
    Chappel
	 	 	 	 
	James Benson	 	 	
	Name of Witness	 	 	 
	(Please print)	 	 	 
	 	 	 	 
	SIGNED by Anne Muriel
    Chappel atf M & A	)	 	 
	Chappel Superfund in the
    presence of:	)	 	 
	 	 	 	 
	/s/ M.H. Chappel	 	 	/s/ Anne Muriel Chappel
	Signature of Witness	 	 	Signature of Anne Muriel Chappel
	 	 	 	 
	M.H. Chappel	 	 	
	Name of Witness	 	 	 
	(Please print)	 	 	 

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 57

    	 	Shareholder Sale Agreement

    

 

	SIGNED by Richard Hiam in the
    presence of:	)	 	 
	 	)	 	 
	 	 	 	 
	/s/ Alastair Winter	 	 	/s/ Richard Hiam
	Signature of Witness	 	 	Signature of Richard Hiam
	 	 	 	 
	Alastair Winter	 	 	
	Name of Witness	 	 	 
	(Please print)	 	 	 
	 	 	 	 
	SIGNED by Hubert Mazure	)	 	 
	in the presence of:	)	 	 
	 	 	 	 
	/s/ Silvia Batic	 	 	/s/ Hubert Mazure
	Signature of Witness	 	 	Signature of Hubert Mazure
	 	 	 	 
	Silvia Batic	 	 	
	Name of Witness	 	 	 
	(Please print)	 	 	 
	 	 	 	 
	SIGNED by Hestanne Mazure	)	 	 
	the presence	)	 	 
	of:	)	 	 
	 	 	 	 
	/s/ Silvia Batic	 	 	/s/ Hestanne Mazure
	Signature of Witness	 	 	Signature of Hestanne Mazure
	 	 	 	 
	Silvia Batic	 	 	
	Name of Witness	 	 	 
	(Please print)	 	 	 
	 	 	 	 
	EXECUTED by Flying Bricks Holdings Pty	)	 	 
	Ltd as trustee for Flying Bricks Super Fund	)	 	 
	and in accordance with section 127(1) of the	)	 	 
	Corporations Act 2001	 	 	 
	 	 	 	 
	/s/ [Illegible]  	 	 	/s/ [Illegible]
	Signature of Director	 	 	Signature of Director / Company Secretary
	 	 	 	(delete as applicable)
	 	 	 	 
	[Illegible]

	 	 	[Illegible]
	Name of Director	 	 	Name of Director / Company Secretary
	(Please print)	 	 	(Please print)

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 58

    	 	Shareholder Sale Agreement

    

 

	SIGNED by
    Ms Susan Louise Wilcox atf	)	 	 
	Williams Super Fund in
    the presence of:	)	 	 
	 	 	 	 
	/s/ Robert Fraser	 	 	/s/ Ms Susan Louise Wilcox
	Signature of Witness	 	 	Signature of Ms Susan Louise
    Wilcox
	 	 	 	 
	Robert Fraser	 	 	 
	Name of Witness	 	 	 
	(Please print)	 	 	 
	 	 	 	 
	SIGNED by Ms Catherine
    Antonia Williams	)	 	 
	atf Williams Super Fund in
    the presence of:	)	 	 
	 	 	 	 
	/s/ Robert Fraser	 	 	/s/ Ms Catherine Antonia Williams
	Signature of Witness	 	 	Signature of Ms Catherine
    Antonia Williams
	 	 	 	 
	Robert Fraser	 	 	 
	Name of Witness	 	 	 
	(Please print)	 	 	 
	 	 	 	 
	SIGNED by Dr Bernard
    Joseph Hudson in the	)	 	 
	presence of: 	)	 	 
	 	 	 	 
	/s/ Lynn Amitrano-hudson	 	 	/s/ Dr Bernard Joseph Hudson
	Signature of Witness	 	 	Signature of Dr Bernard Joseph
    Hudson
	 	 	 	 
	Lynn Amitrano-hudson	 	 	 
	Name of Witness	 	 	 
	(Please print)	 	 	 
	 	 	 	 
	EXECUTED by Teesdale Holdings
    Pty Ltd as	)	 	 
	trustee for Johanson Superfund
    and in	)	 	 
	accordance with section 127(1)
    of the	)	 	 
	Corporations Act 2001	 	 	 
	 	 	 	 
	/s/ C.D. Johanson	 	 	/s/ P.G. Johanson
	Signature of Director	 	 	Signature of Director / Company
    Secretary
		 	 	(delete as applicable)
	 	 	 	
	C.D. Johanson	 	 	P.G. Johanson
	Name of Director	 	 	Name of Director / Company Secretary
	(Please print)	 	 	(Please print)
		 	 	

 

    	Mills Oakley Lawyers Pty Ltd ©	Page 59

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]